[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 239
1. Canis M, Farina M, Jardon K, Rabischong B, Rivoire C, Nohuz E, Botchorishvili R, Pouly JL, Mage G: [Laparoscopy and gynecologic cancer in 2005]. J Gynecol Obstet Biol Reprod (Paris); 2006 Apr;35(2):117-35

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopy and gynecologic cancer in 2005].
  • All the surgical procedures, which may be required to treat a gynecologic cancer, can be performed endoscopically.
  • Animal studies suggested that the risk of tumor dissemination in non traumatized peritoneum is higher after a pneumoperitoneum than after a laparotomy.
  • Changing these parameters we may, in the future, be able to create a peritoneal environment adapted to oncologic patients in order to prevent or to decrease the risks of peritoneal dissemination and/or of postoperative tumor growth.
  • In contrast restaging of an early ovarian cancer initially managed as a benign mass, is a good indication of the laparoscopic approach.
  • Teaching and diffusion of endoscopic oncological techniques are among the major challenges of gynecologic surgery within the next few years.
  • [MeSH-major] Genital Neoplasms, Female / surgery. Laparoscopy
  • [MeSH-minor] Animals. Endometrial Neoplasms / pathology. Endometrial Neoplasms / surgery. Female. Humans. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / epidemiology. Peritoneal Neoplasms / etiology. Pneumoperitoneum, Artificial / adverse effects. Risk Factors. Uterine Cervical Neoplasms / pathology. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16575358.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 190
  •  go-up   go-down


2. Brinton LA, Sakoda LC, Sherman ME, Frederiksen K, Kjaer SK, Graubard BI, Olsen JH, Mellemkjaer L: Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors. Cancer Epidemiol Biomarkers Prev; 2005 Dec;14(12):2929-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of benign gynecologic diseases to subsequent risk of ovarian and uterine tumors.
  • Based on a population-based cohort exceeding 99,000 women, including 2,491 ovarian cancers, 860 borderline ovarian tumors, and 1,398 uterine cancers, we derived relative risks (RR) and 95% confidence intervals (95% CI) associated with overall and histology-specific tumor risks after adjustment for calendar time and reproductive characteristics.
  • [MeSH-minor] Adult. Denmark / epidemiology. Female. Humans. Middle Aged. Proportional Hazards Models. Registries. Risk Assessment. Risk Factors

  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16365012.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  •  go-up   go-down


3. Suzuki N, Yoshioka N, Ohara T, Yokomichi N, Nako T, Yahagi N, Igarashi S, Kobayashi Y, Yoshimatsu M, Takizawa K, Nakajima Y, Kiguchi K, Ishizuka B: Risk factors for perioperative venous thromboembolism: A retrospective study in Japanese women with gynecologic diseases. Thromb J; 2010;8:17

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for perioperative venous thromboembolism: A retrospective study in Japanese women with gynecologic diseases.
  • BACKGROUND: Patients with gynecologic cancer have a high risk of venous thromboembolism (VTE) like patients with other cancers.
  • However, there is little information on risk factors for VTE during gynecologic surgery and no uniform preventive strategy.
  • Our objectives were to identify risk factors for perioperative VTE in gynecologic patients and establish methods for prevention.
  • Thirty-two patients had cancer and seven patients had benign diseases.
  • Multivariate analysis indicated that ovarian cancer, tumor diameter ≥10 cm, and previous of VTE were independent risk factors for preoperative VTE.
  • Among ovarian cancer patients, multivariate analysis showed that an age ≥50 years, the presence of heart disease, clear cell adenocarcinoma, and tumor diameter ≥20 cm were independent risk factors for preoperative VTE.
  • The factors significantly related to preoperative VTE in patients with benign disease included previous VTE, age ≥55 years, tumor diameter ≥20 cm, and a history of allergic-immunologic disease.
  • CONCLUSIONS: Perioperative VTE is often fatal and preventive measures should be taken in the gynecologic field, especially when patients have the risk factors identified in this study.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21054901.001).
  • [ISSN] 1477-9560
  • [Journal-full-title] Thrombosis journal
  • [ISO-abbreviation] Thromb J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2989308
  •  go-up   go-down


Advertisement
4. Cohen P, Tan AL, Penman A: The multidisciplinary tumor conference in gynecologic oncology--does it alter management? Int J Gynecol Cancer; 2009 Dec;19(9):1470-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The multidisciplinary tumor conference in gynecologic oncology--does it alter management?
  • OBJECTIVE: To assess the role of the multidisciplinary tumor conference in patient management in a tertiary gynecologic oncology service.
  • METHODS: Data were analyzed from the records of all patients presented at the gynecologic oncology tumor conferences at Auckland City Hospital from August 1, 2005, to August 1, 2006.
  • Patient information including referral source, cancer site, stage, whether surgery had been performed before the tumor conference and if so where and by whom, and benign versus malignant was extracted from the records.
  • The radiological and pathological findings and diagnosis for each patient both before and after each tumor conference were compared.
  • A discrepancy was defined as a change in tumor site, histological type, grade, or stage that resulted from findings discussed at the conferences.
  • The most common changes to patient management that resulted from the tumor conferences were the addition of chemotherapy and surgery.
  • CONCLUSIONS: This study demonstrates that gynecologic oncology tumor conferences alter the diagnosis in a significant number of cases and therefore affect patient management.
  • [MeSH-minor] Female. Genital Neoplasms, Female / therapy. Humans. Multicenter Studies as Topic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19955920.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


5. Bereman MS, Williams TI, Muddiman DC: Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem; 2009 Feb 1;81(3):1130-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients.
  • In addition, data are compared among samples derived from 10 healthy controls, 10 controls with a differential diagnosis of benign gynecologic tumors, and 10 diseased epithelial ovarian cancer patients (EOC).
  • However, these same glycans provided a significantly less diagnostic value when used to differentiate EOC from benign tumor control samples with an area under the curve of 0.73.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma / diagnosis. Chromatography, Liquid / methods. Glycoproteins / blood. Ovarian Neoplasms / diagnosis. Polysaccharides / blood. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods
  • [MeSH-minor] Female. Genital Neoplasms, Female / chemistry. Genital Neoplasms, Female / diagnosis. Humans. Hydrophobic and Hydrophilic Interactions. Lectins / blood. Lectins / chemistry. Male. ROC Curve

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochim Biophys Acta. 1999 Dec 6;1473(1):4-8 [10580125.001]
  • [Cites] Anal Chem. 2008 Oct 1;80(19):7534-42 [18778038.001]
  • [Cites] Fresenius J Anal Chem. 2000 Mar-Apr;366(6-7):669-76 [11225778.001]
  • [Cites] Biochem J. 2001 Jul 1;357(Pt 1):167-82 [11415447.001]
  • [Cites] Rapid Commun Mass Spectrom. 2001;15(19):1862-8 [11565105.001]
  • [Cites] J Am Soc Mass Spectrom. 2002 Apr;13(4):402-7 [11951978.001]
  • [Cites] Cancer Metastasis Rev. 2001;20(3-4):245-77 [12085965.001]
  • [Cites] Rapid Commun Mass Spectrom. 2002;16(13):1320-9 [12112260.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10231-3 [12149519.001]
  • [Cites] J Chromatogr A. 2002 Aug 30;968(1-2):89-100 [12236519.001]
  • [Cites] Anal Biochem. 2003 May 1;316(1):15-22 [12694722.001]
  • [Cites] Clin Exp Metastasis. 2003;20(2):143-52 [12705635.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):28619-34 [12734200.001]
  • [Cites] Nat Rev Cancer. 2004 Jan;4(1):45-60 [14681689.001]
  • [Cites] Anal Chem. 2004 Feb 1;76(3):833-8 [14750882.001]
  • [Cites] Mass Spectrom Rev. 2004 May-Jun;23(3):161-227 [14966796.001]
  • [Cites] Rapid Commun Mass Spectrom. 2004;18(19):2282-92 [15384149.001]
  • [Cites] J Natl Cancer Inst. 1978 Oct;61(4):961-5 [309009.001]
  • [Cites] J Chromatogr. 1979 Apr 11;162(4):507-28 [528665.001]
  • [Cites] Anal Biochem. 1982 Jan 15;119(2):351-9 [7041698.001]
  • [Cites] Anal Chem. 1990 Feb 1;62(3):248-52 [2305955.001]
  • [Cites] J Chromatogr. 1990 Jan 19;499:177-96 [2324207.001]
  • [Cites] Methods Enzymol. 1990;193:647-60 [2074840.001]
  • [Cites] J Chromatogr. 1993 Sep 3;646(2):317-26 [8408434.001]
  • [Cites] Anal Chem. 1996 Sep 15;68(18):3215-23 [8797382.001]
  • [Cites] Anal Chem. 1997 Nov 15;69(22):4530-5 [9375514.001]
  • [Cites] Anal Chem. 1998 Dec 1;70(23):4951-9 [9852781.001]
  • [Cites] Bioessays. 1999 May;21(5):412-21 [10376012.001]
  • [Cites] Biochemistry. 1964 Jan;3:113-20 [14114492.001]
  • [Cites] Anal Chem. 2005 Feb 1;77(3):886-94 [15679358.001]
  • [Cites] Glycobiology. 2005 Dec;15(12):1332-40 [16037490.001]
  • [Cites] Mol Cell Proteomics. 2005 Dec;4(12):2010-21 [16249172.001]
  • [Cites] Proteomics. 2005 Dec;5(18):4665-72 [16281179.001]
  • [Cites] Glycobiology. 2006 Feb;16(2):132-45 [16177264.001]
  • [Cites] J Chromatogr A. 2006 Jan 27;1103(2):296-306 [16364349.001]
  • [Cites] J Proteome Res. 2006 Jul;5(7):1626-35 [16823970.001]
  • [Cites] Mol Cell Proteomics. 2007 Jan;6(1):43-55 [16847285.001]
  • [Cites] Rapid Commun Mass Spectrom. 2007;21(5):807-11 [17279479.001]
  • [Cites] Anal Chem. 2007 Jul 1;79(13):5051-7 [17539604.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] Biochemistry. 2008 Mar 11;47(10):3155-61 [18260648.001]
  • [Cites] J Proteome Res. 2008 Mar;7(3):1109-17 [18237112.001]
  • [Cites] Proteomics. 2008 Apr;8(7):1384-97 [18318007.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1650-9 [18311910.001]
  • [Cites] Anal Bioanal Chem. 2008 May;391(1):289-97 [18327675.001]
  • [Cites] J Proteome Res. 2008 Jun;7(6):2562-8 [18422354.001]
  • [Cites] Clin Chem. 2008 Jul;54(7):1166-75 [18487288.001]
  • [Cites] Anal Chem. 2008 Aug 1;80(15):6119-26 [18593198.001]
  • [Cites] J Am Soc Mass Spectrom. 2008 Aug;19(8):1138-46 [18511294.001]
  • [Cites] J Mass Spectrom. 2008 Sep;43(9):1215-23 [18324610.001]
  • [Cites] J Proteome Res. 2008 Sep;7(9):3776-88 [18642944.001]
  • [Cites] Mass Spectrom Rev. 1999 Nov-Dec;18(6):349-450 [10639030.001]
  • (PMID = 19113831.001).
  • [ISSN] 1520-6882
  • [Journal-full-title] Analytical chemistry
  • [ISO-abbreviation] Anal. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R33 CA105295; United States / NCI NIH HHS / CA / R33 CA105295
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Lectins; 0 / Polysaccharides; 0 / fucose-binding lectin
  • [Other-IDs] NLM/ NIHMS496567; NLM/ PMC3739471
  •  go-up   go-down


6. Galani P, Kapetanakis S, Papadopoulos C, Dimitrakopoulou G, Kosma L, Lafoyianni S, Dimitrakova E, Papathanasiou J, Fiska A: Hypovolemic shock due to giant uterus leiomyoma detachment. Akush Ginekol (Sofiia); 2010;49(5):68-71
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Uterine leiomyoma (UL) is the most common benign gynecologic tumor of the reproductive age females.
  • [MeSH-minor] Female. Humans. Middle Aged. Uterus / pathology. Uterus / surgery

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21265397.001).
  • [ISSN] 0324-0959
  • [Journal-full-title] Akusherstvo i ginekologii︠a︡
  • [ISO-abbreviation] Akush Ginekol (Sofiia)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Bulgaria
  •  go-up   go-down


7. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC Jr, Lokshin A: Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol; 2010 Jun;117(3):440-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass.
  • Our subject group consisted of women diagnosed with benign masses and early- and late-stage ovarian cancer.
  • RESULTS: More than half of the biomarkers tested were found to differ significantly between benign and malignant cases.
  • As individual markers, HE4 and CA-125 provided the greatest level of discrimination between benign and malignant cases, and the combination of these two biomarkers provided a higher level of discriminatory power than either marker considered alone.
  • Multivariate statistical analysis identified several multimarker panels that could discriminate early-stage, late-stage, and combined ovarian cancers from benign cases with similar or slightly improved SN/SP levels to the CA-125/HE4 combination; however, these larger panels could not outperform the 2-biomarker panel in an independent validation set.
  • CONCLUSIONS: Our findings serve to advance the development of blood-based screening methods for the discrimination of benign and malignant ovarian masses by confirming and expanding upon the superior utility of the CA-125/HE4 combination.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Int J Cancer Suppl. 1988;3:61-7 [3209301.001]
  • [Cites] Cancer. 1987 Aug 1;60(3):353-61 [3594371.001]
  • [Cites] Gynecol Oncol. 1992 Nov;47(2):203-9 [1468698.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):707-13 [7687515.001]
  • [Cites] Gynecol Oncol. 1995 Mar;56(3):402-5 [7535720.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):111-6 [7557595.001]
  • [Cites] Cancer. 1997 May 1;79(9):1647-55 [9128978.001]
  • [Cites] ORL J Otorhinolaryngol Relat Spec. 1997 Mar-Apr;59(2):106-14 [9166881.001]
  • [Cites] Am Fam Physician. 1998 May 15;57(10):2471-6, 2479-80 [9614415.001]
  • [Cites] Oncology. 2004;67(3-4):225-30 [15557783.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Hum Cell. 2004 Dec;17(4):203-9 [16035505.001]
  • [Cites] J Natl Cancer Inst. 2006 Feb 1;98(3):172-80 [16449677.001]
  • [Cites] Mol Cancer Ther. 2006 Feb;5(2):382-90 [16505113.001]
  • [Cites] Clin Obstet Gynecol. 2006 Sep;49(3):448-58 [16885652.001]
  • [Cites] Cancer. 2007 May 1;109(9):1887-96 [17373668.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):402-8 [18061248.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] Biochim Biophys Acta. 2008 Apr;1785(2):232-65 [18291115.001]
  • [Cites] Obstet Gynecol Clin North Am. 2008 Jun;35(2):271-84, ix [18486841.001]
  • [Cites] Br J Cancer. 2008 Oct 7;99(7):1103-13 [18766180.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81 [18843033.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):40-6 [18851871.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Clin Cancer Res. 2009 Apr 15;15(8):2647-56 [19351767.001]
  • [Cites] Am J Obstet Gynecol. 2009 Jun;200(6):639.e1-5 [19285648.001]
  • [Cites] J Clin Oncol. 2010 May 1;28(13):2159-66 [20368574.001]
  • [Cites] Am J Obstet Gynecol. 1988 Aug;159(2):341-6 [2457318.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):141-5 [10843472.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82 [11520365.001]
  • [Cites] J Clin Oncol. 2002 Mar 1;20(5):1248-59 [11870167.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] Obstet Gynecol. 2003 Sep;102(3):499-505 [12962932.001]
  • [Cites] Gynecol Oncol. 2003 Sep;90(3):662-6 [13678742.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Nurs Clin North Am. 1992 Dec;27(4):835-45 [1448359.001]
  • (PMID = 20334903.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642-03; United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / R01 CA108990; United States / NCI NIH HHS / CA / R01 CA098642-02; United States / NCI NIH HHS / CA / R01 CA098642-01A1; United States / NCI NIH HHS / CA / R01 CA108990-02; United States / NCI NIH HHS / CA / R01 CA108990-01; United States / NCI NIH HHS / CA / R01 CA108990-05; United States / NCI NIH HHS / CA / R01 CA108990-04; United States / NCI NIH HHS / CA / R01 CA108990-05S1; United States / NCI NIH HHS / CA / R01 CA098642-04; United States / NCI NIH HHS / CA / R01 CA108990-01A1; United States / NCI NIH HHS / CA / R01 CA108990-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  • [Other-IDs] NLM/ NIHMS192224; NLM/ PMC2873171
  •  go-up   go-down


8. Narayanan P, Iyngkaran T, Sohaib SA, Reznek RH, Rockall AG: Pearls and pitfalls of MR lymphography in gynecologic malignancy. Radiographics; 2009 Jul-Aug;29(4):1057-69; discussion 1069-71
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pearls and pitfalls of MR lymphography in gynecologic malignancy.
  • Dissemination of tumor to lymph nodes is one of the principal routes of metastatic disease.
  • The presence or absence of nodal disease is an important prognostic factor in gynecologic malignancies; thus, nodal staging is an integral part of the pretreatment assessment.
  • The contrast agent is taken up by macrophages within benign lymph nodes and allows differentiation from malignant nodes on the basis of alterations in signal intensity.
  • [MeSH-major] Dextrans. Diagnostic Errors / prevention & control. Ferrosoferric Oxide. Genital Neoplasms, Female / diagnosis. Image Enhancement / methods. Lymph Nodes / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Contrast Media. Female. Humans. Lymphatic Metastasis. Magnetite Nanoparticles

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19605656.001).
  • [ISSN] 1527-1323
  • [Journal-full-title] Radiographics : a review publication of the Radiological Society of North America, Inc
  • [ISO-abbreviation] Radiographics
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media; 0 / Magnetite Nanoparticles; 0 / ferumoxtran-10; K3R6ZDH4DU / Dextrans; XM0M87F357 / Ferrosoferric Oxide
  • [Number-of-references] 42
  •  go-up   go-down


9. De Gaetano AM, Calcagni ML, Rufini V, Valentini AL, Gui B, Giordano A, Bonomo L: Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls. Abdom Imaging; 2009 Nov;34(6):696-711
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of gynecologic malignancies with FDG PET-CT: case examples, physiologic activity, and pitfalls.
  • The utilization of 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET) in combination with computed tomography (CT) in the assessment of gynecologic malignancies has been rapidly growing in recent years; however, its role in clinical practice has yet to be established.
  • Increased uptake has also been reported in many benign pelvic processes and in premenopausal patients; endometrial activity changes cyclically, whereas increased ovarian uptake may be functional.
  • FDG PET-CT has an emerging role in staging nodal disease and in the evaluation of local recurrence or peritoneal spread of gynecologic malignancies and is also useful in monitoring response to therapy and in long-term follow-up.
  • FDG PET-CT is most suitable in patients with high tumor markers and negative or uncertain conventional imaging data.
  • [MeSH-major] Fluorodeoxyglucose F18. Genital Neoplasms, Female / radiography. Genital Neoplasms, Female / radionuclide imaging. Radiopharmaceuticals. Tomography, Emission-Computed / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Female. Humans. Neoplasm Recurrence, Local / radiography. Neoplasm Recurrence, Local / radionuclide imaging. Sensitivity and Specificity. Whole Body Imaging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791682.001).
  • [ISSN] 1432-0509
  • [Journal-full-title] Abdominal imaging
  • [ISO-abbreviation] Abdom Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 75
  •  go-up   go-down


10. Young RH: Dusting off another shelf: further comments on classic gynecologic pathology books of yesteryear. Int J Gynecol Pathol; 2005 Jan;24(1):100-10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dusting off another shelf: further comments on classic gynecologic pathology books of yesteryear.
  • Selected outstanding books from the older literature on gynecologic pathology are reviewed with emphasis on drawing attention to the abundant helpful information and often outstanding illustrations that are worthy of review by present-day pathologists.
  • Each of them emphasizes the time-honored problem of mimicry of malignancy by diverse benign lesions or even aspects of normal histology.
  • Teilum's book contains a masterful account of the histopathology of germ cell tumors emphasizing a neoplasm with which his name will always be associated, the yolk sac tumor (endodermal sinus tumor).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626924.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Historical Article; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Miura N, Kanamori Y, Takahashi M, Sato R, Tsukamoto T, Takahashi S, Harada T, Sano A, Shomori K, Harada T, Kigawa J, Ito H, Terakawa N, Hasegawa J, Shiota G: A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies. Oncol Rep; 2007 Mar;17(3):541-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A diagnostic evaluation of serum human telomerase reverse transcriptase mRNA as a novel tumor marker for gynecologic malignancies.
  • By this method, we attempted to elucidate the diagnostic evaluation of serum hTERT mRNA for gynecologic malignancies.
  • In 174 female patients with gynecological lesions (47 with ovarian lesions, 63 with uterine lesions, 2 with malignancies in other gynecological lesions, and 62 benign lesions) and 20 healthy individuals, we measured serum hTERT mRNA and EGFR mRNA by using the newly developed real-time quantitative RT-PCR.
  • We examined their sensitivity and specificity in cancer diagnosis, clinical significance in comparison with conventional tumor markers, and their correlations with the clinical parameters by using multivariate analyses.
  • Serum hTERT mRNA showed higher values in patients with gynecologic cancers than in those with benign diseases and healthy individuals.
  • EGFR mRNA did not display any differences between the diseases. hTERT mRNA is useful for diagnosing gynecologic cancer and is superior to conventional tumor markers.
  • Therefore, serum hTERT mRNA is a novel and available biomarker for gynecologic malignancies.
  • [MeSH-major] Biomarkers, Tumor / blood. Genital Neoplasms, Female / blood. Genital Neoplasms, Female / diagnosis. Telomerase / blood
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Middle Aged. RNA, Messenger / blood. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17273731.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


12. Mittal K, Joutovsky A: Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas. Gynecol Oncol; 2007 Feb;104(2):362-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Areas with benign morphologic and immunohistochemical features are associated with some uterine leiomyosarcomas.
  • All slides from the grossly recognized tumor were evaluated for the degree of atypia and mitotic counts within the leiomyosarcomas.
  • Morphologically benign tumor areas were identified in 5 of the 11 tumors.
  • These morphologically benign areas showed a p53 expression of 1% in each of the 4 cases, with low MIB-1 (5 to 15%) and high ER/PR expression (ER: 50-100%, PR: 10-100%).
  • The benign and malignant areas merged in all cases.
  • Morphologic and immunohistochemical spectrum of changes from benign to malignant is seen in 50% of LMS.
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Ki-67 Antigen / analysis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17011615.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


13. Cheewakriangkrai C, Sharma S, Deeb G, Lele S: A rare female genital tract tumor: benign granular cell tumor of vulva: case report and review of the literature. Gynecol Oncol; 2005 May;97(2):656-8
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A rare female genital tract tumor: benign granular cell tumor of vulva: case report and review of the literature.
  • BACKGROUND: The granular cell tumor (GCT) of vulva is a rare female genital tract tumor.
  • CASE: A 59-year-old female was incidentally noted to have a 1-cm sized lump in her left labium majus that subsequently increased in size to approximately 4 cm.
  • Histologic examination of the tumor showed sheets and clusters of infiltrating tumor cells with morphologic features consistent with granular cell tumor.
  • CONCLUSION: Although benign and slow growing, it has a tendency for recurrence and can cause morbidity and mortality when presenting with multicentric or multiple organ involvement due to the lack of effective systemic therapy.
  • [MeSH-major] Granular Cell Tumor / pathology. Vulvar Neoplasms / pathology
  • [MeSH-minor] Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15863174.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


14. Chen L, Homesley HD, Scribner DR Jr, Cantuaria GH, He Q, Cheek RL, Whitehead CM, Doobay H, Fischer TJ: Performance of a biomarker panel to identify malignancy within a pelvic mass population. J Clin Oncol; 2009 May 20;27(15_suppl):5566

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we evaluated the performance of a subset of these markers in differentiating ovarian cancer from benign pelvic mass.
  • Pathology showed 76 cases of epithelial ovarian carcinoma (EOC), 17 borderline tumors, 11 other gynecologic cancers, and 150 benign masses.
  • All calculations compared the benign vs. EOC and borderline tumor populations.
  • The combination of CA125, HE4 and glycodelin exhibited the highest overall performance in identifying malignancy from benign masses, demonstrating 80% sensitivity, 80% specificity in patients <55 years, and 89% sensitivity, 80% specificity in patients ≥55.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962561.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Szymanska-Pasternak J, Szymanska A, Medrek K, Imyanitov EN, Cybulski C, Gorski B, Magnowski P, Dziuba I, Gugala K, Debniak B, Gozdz S, Sokolenko AP, Krylova NY, Lobeiko OS, Narod SA, Lubinski J: CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors. Gynecol Oncol; 2006 Sep;102(3):429-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CHEK2 variants predispose to benign, borderline and low-grade invasive ovarian tumors.
  • We included 539 Polish women with benign ovarian cystadenomas, 122 women with borderline ovarian malignancies and 447 women with invasive ovarian cancer.
  • CONCLUSION: These data indicate that CHEK2 variants may predispose to a range of ovarian tumor types of low malignant potential, but not to aggressive cancers.
  • [MeSH-minor] Checkpoint Kinase 2. Female. Genetic Variation. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16828850.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


16. Khan N, Oriuchi N, Yoshizaki A, Kanuma T, Higuchi T, Endo K: Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer. Ann Nucl Med; 2005 Apr;19(2):137-45
Genetic Alliance. consumer health - Metastatic cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer.
  • PURPOSE: This study evaluated the diagnostic role and accuracy of positron emission tomography (PET) using 2-[F-18]fluoro-2-deoxy-D-glucose (FDG) for the detection of tumor foci in patients with suspected recurrent or metastatic lesions of gynecologic cancers.
  • MATERIALS AND METHODS: FDG PET imaging was performed on 51 patients with a previous history of gynecologic cancer who were referred for a clinical suspicion of recurrent disease.
  • Malignant lesions accumulated significantly more FDG than the benign ones (the mean SUVs were 3.7 +/- 1.9 and 1.6 +/- 1.1, respectively, p = 0.004).
  • The sensitivity and specificity in correct identification of tumor recurrence or metastases using a threshold SUV 1.9 were 88.8% and 66.7% in contrast to the visual analysis (sensitivity 96.4%, specificity 50%) on a lesion-based analysis.
  • FDG PET was valuable when CT/MRI was negative or inconclusive, and in patients with elevated tumor marker levels as well as with normal tumor marker levels when recurrence was suspected clinically.
  • However, PET failed to visualize some small metastatic lesions in lung and bone, and showed falsely high FDG uptake in some benign lesions.
  • CONCLUSION: The results indicated that FDG PET is a reliable and accurate diagnostic method for detecting recurrent or metastatic gynecologic cancer particularly lymph node metastases.
  • [MeSH-major] Carcinoma / radionuclide imaging. Carcinoma / secondary. Fluorodeoxyglucose F18. Genital Neoplasms, Female / radionuclide imaging. Genital Neoplasms, Female / secondary. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Radiopharmaceuticals. Reproducibility of Results. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909494.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


17. Wang CL, Tsai EM, Liu CM, Wu CH, Long CY: Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure. Gynecol Obstet Invest; 2007;63(1):28-30
MedlinePlus Health Information. consumer health - Pelvic Support Problems.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidental finding of a benign bladder tumor during the tension-free vaginal tape procedure.
  • However, concomitant resection of a bladder tumor during the TVT procedure is rare.
  • A bladder tumor located in the trigone was found incidentally during cystoscopy.
  • Concomitant resection of the bladder tumor was performed following the TVT procedure.
  • The surgical result of our patient suggests that concomitant resection of a benign intravesical pathology with TVT procedure is safe and effective.
  • [MeSH-minor] Female. Humans. Incidental Findings. Middle Aged. Suburethral Slings

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16864984.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 13
  •  go-up   go-down


18. Padovan RS, Kralik M, Prutki M, Hrabak M, Oberman B, Potocki K: Cross-sectional imaging of the pelvic tumors and tumor-like lesions in gynecologic patients-misinterpretation points and differential diagnosis. Clin Imaging; 2008 Jul-Aug;32(4):296-302
MedlinePlus Health Information. consumer health - MRI Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cross-sectional imaging of the pelvic tumors and tumor-like lesions in gynecologic patients-misinterpretation points and differential diagnosis.
  • Computed tomography and/or magnetic resonance imaging were performed in 42 female patients with suspected pelvic mass.
  • One benign cyst and one case of postirradiation fibrosis were characterized as recurrent tumors, one surgically transposed ovary as metastasis, and an ovarian torsion as ovarian tumor, and a pelvic hematoma was mistaken for abscess.
  • [MeSH-major] Genital Diseases, Female / diagnosis. Magnetic Resonance Imaging. Pelvic Neoplasms / diagnosis. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Diagnosis, Differential. Diagnostic Errors. Female. Genital Neoplasms, Female / diagnosis. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18603185.001).
  • [ISSN] 1873-4499
  • [Journal-full-title] Clinical imaging
  • [ISO-abbreviation] Clin Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Korkontzelos I, Tsimoyiannis E, Zagaliki A, Demou A, Karabina E, Antoniou N: Pelvic retroperitoneal schwannoma presenting as a gynecologic mass: case report. Eur J Gynaecol Oncol; 2005;26(1):117-9
Genetic Alliance. consumer health - Schwannoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pelvic retroperitoneal schwannoma presenting as a gynecologic mass: case report.
  • Schwannomas of the sacral plexus are retroperitoneal tumors, usually benign, that result from proliferation of perineural cells.
  • They are rare, pelvic, well defined tumors that present infrequently as gynecologic masses.
  • Imaging methods suggested that this tumor was most probably an ovarian mass of embryonic origin.
  • The goal of the operating intervention is to excise the tumor avoiding major trauma, thus cooperation between surgeons is indispensable.
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Laparotomy. Ovarian Neoplasms / diagnosis. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15755018.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


20. Auner V, Sehouli J, Oskay-Oezcelik G, Horvat R, Speiser P, Zeillinger R: ABC transporter gene expression in benign and malignant ovarian tissue. Gynecol Oncol; 2010 May;117(2):198-201
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ABC transporter gene expression in benign and malignant ovarian tissue.
  • METHODS: Real-time PCR was used to determine RNA expression levels of 9 ABC transporters in 50 benign tissue samples and 50 recurrent ovarian cancer samples.
  • RESULTS: Gene expression of four transporters (ABCC1, ABCC2, ABCC3, and ABCB3) was significantly elevated in recurrent cancer lesions compared to benign tissue.
  • A significant difference between primary and recurrent tumor tissue was found in all four genes.
  • Changes in gene expression between benign samples and primary lesions were minor and not relevant.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Cystadenoma / genetics. Cystadenoma / metabolism. Cystadenoma / pathology. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Gene Expression. Humans. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Neoplasm Staging. Paclitaxel / administration & dosage. ROC Curve. Up-Regulation

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19922990.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 8N3DW7272P / Cyclophosphamide; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA: Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers. Gynecol Oncol; 2008 Jan;108(1):141-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.
  • We investigated the expression patterns of MISIIR in benign and malignant gynecologic tissues and benign non-gynecologic tissues to better assess the relevance of MISIIR as a target for new therapeutic and diagnostic approaches to gynecologic cancers.
  • EOC cell lines (10), primary EOCs (12), and tissue microarrays (TMAs) containing benign gynecologic (179) and non-gynecologic tissues (25), EOC (182), endometrial carcinomas (109), uterine sarcomas (98), and ovarian dysgerminomas (22) were examined for MISIIR expression.
  • We observed moderate or strong MISIIR expression via IHC in the majority of gynecologic cancers: EOC 69% (125/182), ovarian dysgerminomas 77% (17/22), endometrial cancers 75% (82/109), uterine malignant mixed Müllerian tumors (MMMT) 59% (30/51), uterine leiomyosarcomas (LMS) 52% (15/29), and endometrial stromal sarcomas (ESS) 22% (4/18).
  • Over 74% of normal non-gynecologic tissues did not express MISIIR.
  • CONCLUSIONS: In the largest study to date, we report that MISIIR is highly expressed by a wide variety of gynecologic cancers, including cancers currently without effective systemic therapies.
  • Low levels of expression in select non-gynecologic tissues coupled with high expression in gynecologic malignancies make MISIIR an attractive target for novel therapeutics and tumor-directed imaging in the management of gynecologic cancers.
  • [MeSH-major] Genital Neoplasms, Female / enzymology. Receptors, Peptide / biosynthesis. Receptors, Transforming Growth Factor beta / biosynthesis
  • [MeSH-minor] Animals. Blotting, Western. CHO Cells. Cell Line, Tumor. Cricetinae. Cricetulus. Female. Humans. Immunohistochemistry. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Transfection

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17988723.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Receptors, Peptide; 0 / Receptors, Transforming Growth Factor beta; 0 / anti-Mullerian hormone receptor
  •  go-up   go-down


22. Zhang X, Wu LY, Li XJ, Li HJ, Zhang R, Liu LY: [Clinical analysis of benign pelvic mass with high serum levels of CA(125)]. Zhonghua Fu Chan Ke Za Zhi; 2005 Mar;40(3):178-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of benign pelvic mass with high serum levels of CA(125)].
  • OBJECTIVE: To investigate serum CA(125) levels and the value of serum CA(125) in differential diagnosis of benign pelvic mass.
  • METHODS: We retrospectively analyzed 492 patients with benign pelvic mass, including 237 cases of benign ovarian tumor and 255 other benign gynecological diseases.
  • Those of ovarian epithelial cancer patients were significantly higher than in benign pelvic mass (P < 0.01).
  • The highest value of CA(125) among all the benign cases was 1281.0 kU/L, which was seen in a case of ovarian thecoma.
  • CONCLUSIONS: Serum CA(125) levels in some benign pelvic mass are higher than the cut-off level of CA(125), such as pelvic tuberculosis, uterine adenomyosis, ovarian fibroma and ovarian endometriosis.
  • The medians of serum CA(125) in benign pelvic mass are much lower than in ovarian epithelial cancer.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Female. Humans. Middle Aged. Retrospective Studies. Tumor Burden. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840313.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / MUC16 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


23. Onuma K, Dabbs DJ, Bhargava R: Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium. Int J Gynecol Pathol; 2008 Jul;27(3):418-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mammaglobin expression in the female genital tract: immunohistochemical analysis in benign and neoplastic endocervix and endometrium.
  • Mammaglobin (MGB), a secretory protein belonging to the uteroglobin/Clara cell protein family, is a sensitive marker for breast carcinoma, but is also reported to be expressed in the female genital tract and its neoplasms.
  • Details of MGB expression pattern and its pathologic significance in the female genital tract have not been systematically studied.
  • To investigate the potential use of MGB in gynecologic pathology practice, we tested MGB expression by immunohistochemistry on 47 endocervical adenocarcinomas (whole tissue sections of 13 invasive and 35 in situ) and 55 endometrial carcinomas (39 endometrioid and 16 nonendometrioid represented on a single tissue microarray).
  • Endocervical adenocarcinoma in situ (AIS) showed either weak (predominantly) or moderate (occasionally) expression in about 40% of the cases in comparison with strong positivity in benign endocervical glandular epithelium.
  • Reduction of MGB staining was seen in transition from benign epithelium to AIS.
  • Most endocervical adenocarcinomas are negative for MGB, in contrast to mostly positive endometrioid endometrial adenocarcinomas, however, MGB expression alone is not specific enough to distinguish these 2 tumor types.
  • MGB may be a promising new adjunctive marker in gynecologic pathology.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Carcinoma in Situ / metabolism. Neoplasm Proteins / biosynthesis. Uterine Neoplasms / metabolism. Uteroglobin / biosynthesis. Uterus / metabolism
  • [MeSH-minor] Cervix Uteri / metabolism. Endometrial Neoplasms / metabolism. Endometrium / metabolism. Female. Humans. Immunohistochemistry. Mammaglobin A. Uterine Cervical Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580321.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mammaglobin A; 0 / Neoplasm Proteins; 0 / SCGB2A2 protein, human; 9060-09-7 / Uteroglobin
  •  go-up   go-down


24. Folpe AL, Mentzel T, Lehr HA, Fisher C, Balzer BL, Weiss SW: Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol; 2005 Dec;29(12):1558-75
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature.
  • This family of tumors includes angiomyolipoma (AML), clear cell sugar tumor of the lung (CCST), lymphangioleiomyomatosis (LAM), and very rare tumors in other locations.
  • Because non-AML/non-LAM PEComas are extremely rare and their natural history and prognostic features undefined, we present our experience with 26 PEComas of soft tissue and the gynecologic tract, the largest series to date.
  • The median patient age was 46 years (range, 15-97 years); there was a marked female predominance (22 females, 4 males).
  • Recurrence and/or metastasis was strongly associated tumor size > median size (8 cm), mitotic activity greater than 1/50 HPF, and necrosis.
  • We conclude that PEComas of soft tissue and gynecologic origin may be classified as "benign," "of uncertain malignant potential," or "malignant."
  • Small PEComas without any worrisome histologic features are most likely benign.
  • [MeSH-major] Biomarkers, Tumor / analysis. Epithelioid Cells / pathology. Genital Neoplasms, Female / pathology. Neoplasms, Connective and Soft Tissue / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Follow-Up Studies. Humans. Immunohistochemistry. Immunophenotyping. Male. Middle Aged. Mitosis. Neoplasm Metastasis. Neoplasm Recurrence, Local. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome. Tumor Burden

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16327428.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 56
  •  go-up   go-down


25. Renshaw AA, Hughes JH, Wang E, Haja J, Wilbur D, Henry MR, Moriarty AT, Cytopathology Resource Committee, College of American Pathologists: Leukemia/lymphoma in cerebrospinal fluid: distinguishing between cases that performed well and poorly in the College of American Pathologists Interlaboratory Comparison Program in Non-gynecologic Cytology. Arch Pathol Lab Med; 2006 Dec;130(12):1762-5
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leukemia/lymphoma in cerebrospinal fluid: distinguishing between cases that performed well and poorly in the College of American Pathologists Interlaboratory Comparison Program in Non-gynecologic Cytology.
  • CONTEXT: Although the cytologic features of leukemia/lymphoma in cerebrospinal fluid specimens are well known, the correlation of these features with the ability of cytologists to identify this tumor have not been well studied.
  • DESIGN: The performance of 147 cases of leukemia/lymphoma in the College of American Pathologists Interlaboratory Comparison Program in Non-gynecologic Cytology was analyzed.
  • RESULTS: For all cases of leukemia/lymphoma in the program, the rate of misclassification as benign for cases with Papanicolaou stain was significantly higher than for those with Romanowsky stain (9.5% vs 2.6%, P < .001).
  • The size of the tumor cells and preservation were not significant.
  • CONCLUSION: Cases of specimens of leukemia/lymphoma in cerebrospinal fluid are more likely to be misdiagnosed as benign if they are Papanicolaou-stained or have 200 abnormal cells.

  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17149947.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Nowak M, Glowacka E, Szpakowski M, Szyllo K, Malinowski A, Kulig A, Tchorzewski H, Wilczynski J: Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors. Neuro Endocrinol Lett; 2010;31(3):375-83
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
  • OBJECTIVE: To analyze the profiles of interleukin-2 (IL-2), IL-6, IL-8, IL-10, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta1 (TGF-beta1) and interferon-gamma (IFN-gamma) in serum and the tumor microenvironment (cyst fluid, ascites) in women with ovarian cancer or benign ovarian tumors to find the differences in their immunological status.
  • We also estimated serum cytokines as biomarkers to distinguish preoperatively between malignant or benign character of tumors.
  • POPULATION: 51 women with epithelial ovarian cancer, 26 with benign ovarian tumors of epithelial origin and 21 healthy controls.
  • RESULTS: We did not found differences in the levels of IFN-gamma, TNF-alpha and IL-2 in all fluids isolated from patients with malignant or benign tumors.
  • Women with advanced cancer had significantly higher serum IL-6, IL-10 and TGF-beta1 levels than women with early stages or benign tumors.
  • The concentrations of IL-6 and IL-8 were higher in ascites of cancer patients than in ascites of women with benign tumors.
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20588232.001).
  • [ISSN] 0172-780X
  • [Journal-full-title] Neuro endocrinology letters
  • [ISO-abbreviation] Neuro Endocrinol. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Cytokines
  •  go-up   go-down


27. Jordan SJ, Green AC, Whiteman DC, Webb PM, Australian Ovarian Cancer Study Group: Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol; 2007 Nov;107(2):223-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum?
  • OBJECTIVE: Some molecular and histological evidence suggests that mucinous epithelial ovarian cancers develop via a sequence from benign tumor through borderline tumor to invasive cancer.
  • Such a sequence would predict some shared risk factors between the different tumor types.
  • To investigate this, we examined risk factors for benign, borderline and invasive mucinous ovarian tumors.
  • Women with benign (n=133), borderline (n=147) and invasive (n=43) mucinous tumors of the ovary and women from the general population (n=1487) completed comprehensive health and lifestyle questionnaires.
  • RESULTS: Although parity was inversely related to risk of benign, borderline and invasive tumors, increasing numbers of births did not further decrease risk of any of the tumor types.
  • However, 20 or more pack-years of smoking was associated with a more than twofold increase in risk of all three tumor types (OR=2.7, 95% CI 1.6-4.4 for benign tumors; OR=2.7, 95% CI 1.7-4.4 for borderline tumors; and OR=2.1, 95% CI 0.9-5.0 for invasive cancers) compared to never smoking.
  • Furthermore, patterns of risk factors across benign, borderline and invasive mucinous ovarian tumors are generally consistent with an adenoma-to-carcinoma sequence as the developmental pathway for this subtype of ovarian cancer.
  • [MeSH-minor] Adult. Aged. Australia. Case-Control Studies. Cell Transformation, Neoplastic / pathology. Female. Health Status. Humans. Life Style. Middle Aged. Neoplasm Invasiveness. Odds Ratio. Reproductive History. Risk Assessment. Risk Factors. Smoking / adverse effects. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17662378.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


28. Shibata K, Kajiyama H, Mizokami Y, Ino K, Nomura S, Mizutani S, Terauchi M, Kikkawa F: Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia. Gynecol Oncol; 2005 Jul;98(1):11-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental leucine aminopeptidase (P-LAP) and glucose transporter 4 (GLUT4) expression in benign, borderline, and malignant ovarian epithelia.
  • The authors evaluated P-LAP and GLUT4 expression in benign, borderline, and malignant ovarian epithelia.
  • METHODS: Histologic sections of formalin-fixed, paraffin-embedded specimens from 11 patients with benign serous or mucinous cystadenomas, 14 patients with serous or mucinous borderline tumors, and 80 patients with epithelial-ovarian adenocarcinomas (29 serous, 17 endometrioid, 14 mucinous, and 20 clear cell adenocarcinomas) were stained for P-LAP and GLUT4 using each polyclonal antibody.
  • RESULTS: P-LAP immunoreactivity was detected in 2 of 11 benign cystadenomas.
  • None of the 11 benign ovarian tumors showed any immunoreactivity for GLUT4.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cell Growth Processes / physiology. Cell Line, Tumor. Epithelium / enzymology. Epithelium / metabolism. Female. Glucose Transporter Type 4. Humans. Middle Aged. Neoplasm Invasiveness. Ovarian Diseases / enzymology. Ovarian Diseases / metabolism. Ovarian Diseases / pathology. Transfection

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15907336.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucose Transporter Type 4; 0 / Monosaccharide Transport Proteins; 0 / Muscle Proteins; 0 / SLC2A4 protein, human; EC 3.4.11.3 / Cystinyl Aminopeptidase; EC 3.4.11.3 / leucyl-cystinyl aminopeptidase
  •  go-up   go-down


29. Aviram R, Gassner G, Markovitch O, Cohen I, Fishman A, Tepper R: Volumes of normal ovaries, ovaries with benign lesions, and ovaries with cancer in menopausal women: is there an optimal cut-off value to predict malignancy? J Clin Ultrasound; 2008 Jan;36(1):1-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Volumes of normal ovaries, ovaries with benign lesions, and ovaries with cancer in menopausal women: is there an optimal cut-off value to predict malignancy?
  • PURPOSE: To evaluate different ovarian volume cut-off values to distinguish between normal ovaries, benign lesions, and malignant lesions in menopausal women.
  • METHODS: Transvaginal sonographic ovarian volume measurements were performed in 362 menopausal patients prior to gynecologic surgery.
  • Based on the histopathologic results, a total of 466 ovaries were divided into 3 groups: normal ovary, benign lesion, and malignant tumor.
  • RESULTS: The mean ovarian volumes in the normal ovary, benign lesion, and malignant tumor groups were 3.4 +/- 2.2 cm3 (range, 0.6-9.6 cm3), 102 +/- 308 cm3 (range, 0.3-3543 cm3), and 368 +/- 1176 cm3 (range, 8.1-9908) cm3, respectively.
  • [MeSH-minor] Female. Humans. Mass Screening / standards. Menopause. Middle Aged. Organ Size. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc.
  • (PMID = 17924576.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. de Ruiter GC, Scheithauer BW, Amrami KK, Spinner RJ: Benign metastasizing leiomyomatosis with massive brachial plexus involvement mimicking neurofibromatosis type 1. Clin Neuropathol; 2006 Nov-Dec;25(6):282-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign metastasizing leiomyomatosis with massive brachial plexus involvement mimicking neurofibromatosis type 1.
  • We report the case of a patient who presented with right arm and shoulder pain due to compression of the infraclavicular brachial plexus due to benign metastasizing leiomyomatosis (BML).
  • The diagnosis of BML was not obvious due to its rare nature, the patient's not detailing the specifics of her gynecologic history of having undergone resection of a large uterine leiomyoma and followed by disseminated pelvic leiomyomatous nodules, histologic misinterpretation of an extrauterine lesion of the spine and the brachial plexus as a neurofibroma and the radiologic diagnosis of lung nodules as being "non-specific" in nature.
  • [MeSH-major] Brachial Plexus / pathology. Brachial Plexus Neuropathies / etiology. Brachial Plexus Neuropathies / pathology. Leiomyoma / pathology. Neoplasm Metastasis / pathology. Neurofibromatosis 1 / diagnosis. Peripheral Nervous System Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Decompression, Surgical. Diagnosis, Differential. Diagnostic Errors / prevention & control. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Pain / etiology. Pain / pathology. Pain / physiopathology. Spinal Neoplasms / pathology. Spinal Neoplasms / physiopathology. Treatment Outcome


31. Tsao KC, Hong JH, Wu TL, Chang PY, Sun CF, Wu JT: Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis. J Clin Lab Anal; 2007;21(3):193-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevation of CA 19-9 and chromogranin A, in addition to CA 125, are detectable in benign tumors in leiomyomas and endometriosis.
  • As the best-known tumor marker for ovarian carcinoma, CA 125 has also been commonly used to monitor patients with common benign gynecologic diseases such as endometriosis and leiomyoma.
  • Both of these benign tumors are known to be at risk of developing into cancer.
  • During the screening of an asymptomatic population with multiple tumor markers, including alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), CA 125, CA 19-9, CA 15-3, chromogranin A (CgA), and squamous cell carcinoma antigen (SCC), we have detected elevated tumor markers in 142 individuals; 19 of them were diagnosed with endometriosis or leiomyoma or both.
  • In addition to the detection of elevation of CA 125 in these benign tumors, elevated CA 19-9 or CgA was also found in these patients with endometriosis or leiomyoma.
  • It appears that instead of monitoring only CA 125, as is traditionally done, multiple tumor markers, including CA 19-9, CgA, and CA 125, should be measured simultaneously in women with clinical disorders associated with the ovary or uterus in order to detect gynecologic benign tumors and in order to prevent further development of cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Chromogranin A / blood. Endometrial Neoplasms / blood. Endometriosis / blood. Leiomyoma / blood
  • [MeSH-minor] Female. Humans. Mass Screening / methods


32. Wang CJ, Chao A, Lai CH, Huang SY, Lee CL, Soong YK: Laparoscopically assisted vaginal ovarian cystectomy for clinically diagnosed benign large ovarian masses. J Laparoendosc Adv Surg Tech A; 2009 Oct;19(5):623-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopically assisted vaginal ovarian cystectomy for clinically diagnosed benign large ovarian masses.
  • MATERIALS AND METHODS: Among the medical records of 324 patients with ovarian masses, 10 consecutive women of reproductive age with prior sexual activity and with large ovarian masses (10-27 cm) were evaluated.
  • The median (range) tumor size was 15.5 cm (range, 10-27), operative duration was 62 minutes (range, 31-110), the estimated blood loss 50 mL (range, 10-150), and the hospital stay was 2 days (range, 1-4).
  • [MeSH-major] Cystadenoma / surgery. Gynecologic Surgical Procedures / methods. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Cystadenoma, Mucinous / surgery. Cystadenoma, Serous / surgery. Female. Humans. Laparoscopy. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19715487.001).
  • [ISSN] 1557-9034
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


33. Akçay T, Dinçer Y, Alademir Z, Aydinli K, Arvas M, Demirkiran F, Kösebay D: Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors. Eur J Obstet Gynecol Reprod Biol; 2005 Mar 1;119(1):108-13
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significance of the O6-methylguanine-DNA methyltransferase and glutathione S-transferase activity in the sera of patients with malignant and benign ovarian tumors.
  • OBJECTIVE: To demonstrate O6-methylguanine-DNA methyltransferase (MGMT) and glutathione S-transferase (GST) activities by analyzing the sera separately obtained from patients with malignant ovarian tumors, benign ovarian tumors, and healthy individuals.
  • STUDY DESIGN: Fourty-nine patients with ovarian cancer, nine patients with benign tumors, and 22 healthy women were included in this study.
  • Blood samples were obtained from all the subjects in the malignant-tumor, benign-tumor, and control groups.
  • RESULTS: Our work demonstrated that untreated patients with malignant ovarian tumors revealed significantly greater MGMT and GST activities in their sera than did both healthy individuals and patients with benign ovarian tumors, while no significant difference was found between the healthy group and the patients with benign ovarian tumors with respect to their sera MGMT and GST activities.
  • A relationship between sera MGMT and GST activities, tumor histology and pathology was not found in this study.
  • [MeSH-major] Biomarkers, Tumor / blood. Glutathione Transferase / blood. Neoplasms, Glandular and Epithelial / blood. O(6)-Methylguanine-DNA Methyltransferase / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Paclitaxel / administration & dosage

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15734094.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase; EC 2.5.1.18 / Glutathione Transferase; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


34. Begum FD, Høgdall E, Kjaer SK, Blaakaer J, Christensen IJ, Christensen L, Høgdall C: Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecol Oncol; 2009 May;113(2):221-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors.
  • Another aim is to find new diagnostic markers, which may select patients at high risk for OC for quick referral to highly specialized centers in gynecologic oncology.
  • METHODS: The potential ability of the markers to discriminate between the four groups (208 benign ovarian tumor, 153 borderline ovarian tumor (BOT), 445 OC and 1333 age matched controls) in OC screening was examined.
  • We also constructed a risk assessment index (RAI) for discrimination between tumor groups based on these variables and menopausal status.
  • A very high probability of having OC or a benign tumor, respectively, was predicted by the RAI.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Lectins, C-Type / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Staging. Ovarian Diseases / blood. Ovarian Diseases / diagnosis. Ovarian Diseases / pathology. Postmenopause / blood. Premenopause / blood. Preoperative Care. Risk Assessment

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261323.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Lectins, C-Type; 109489-77-2 / tetranectin
  •  go-up   go-down


35. Liu YN, Ye X, Cheng HY, Cheng YX, Fu TY, Chen J, Chang XH, Cui H: [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors]. Zhonghua Fu Chan Ke Za Zhi; 2010 May;45(5):363-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].
  • OBJECTIVE: To investigate the value of human epididymis secretory protein 4(HE4) combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian malignant tumor.
  • METHODS: The level of HE4 and CA125 were measured by enzyme-linked immunosorbent assay (ELISA) in the serum specimens of 46 cases in endometriosis cyst group, 36 cases in malignant ovarian tumor group, 60 cases in benign ovarian diseases and 50 women in healthy women group.
  • (1) HE4: the median levels of HE4 were 52.4, 51.0, 50.0 pmol/L in group of endometriosis, normal control and benign ovarian tumor, which didn't show statistical difference.
  • However, HE4 was 507.5 pmol/L in ovarian cancer group, which was significantly higher than those of 3 groups (P<0.05). (2) CA125: there were significant different in median level of CA125 was observed as 743.0 kU/L in ovarian cancer, 84.9 kU/L in endoemtriosis, 15.4 kU/L in benign ovarian disease, and 11.5 kU/L in healthy women (P<0.05). (3) The single assay: when compared with that in endometriosis group, receiver operating characteristic area under the curve (ROC-AUC) were 0.933 in HE4 alone and 0.821 in CA125 alone assay in ovarian cancer group.
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / blood. Case-Control Studies. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. ROC Curve. Sensitivity and Specificity. Young Adult

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20646446.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Epididymal Secretory Proteins
  •  go-up   go-down


41. Forde GK, Harrison C, Doss BJ, Forde AE, Carlson JW: Bilateral and multinodular signet-ring stromal tumor of the ovary. Obstet Gynecol; 2010 Aug;116 Suppl 2:556-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral and multinodular signet-ring stromal tumor of the ovary.
  • BACKGROUND: Signet-ring stromal tumor of the ovary is a rare, benign sex cord stromal tumor that is typically unilateral.
  • Its distinction from malignant signet-ring cell adenocarcinoma metastatic to the ovary (Krukenberg tumor), is critical.
  • CONCLUSION: We report a rare example of signet-ring stromal tumor that is bilateral and multinodular mimicking a Krukenberg tumor.
  • [MeSH-major] Krukenberg Tumor / diagnosis. Ovarian Neoplasms / pathology. Sex Cord-Gonadal Stromal Tumors / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664453.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Hahm TS, Ham JS, Kang JY: Unilateral massive hydrothorax in a gynecologic patient with pseudo-Meigs' syndrome -A case report-. Korean J Anesthesiol; 2010 Feb;58(2):202-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unilateral massive hydrothorax in a gynecologic patient with pseudo-Meigs' syndrome -A case report-.
  • Pseudo-Meigs' syndrome is characterized by the presence of a benign ovarian tumor associated with ascites and a right-sided hydrothorax.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Obstet Gynaecol Res. 2005 Jun;31(3):257-62 [15916664.001]
  • [Cites] Obstet Gynecol. 1954 May;3(5):471-86 [13154792.001]
  • [Cites] Am J Obstet Gynecol. 1954 May;67(5):962-85 [13148256.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1999 Jan;82(1):97-9 [10192495.001]
  • [Cites] Chest Surg Clin N Am. 1998 May;8(2):449-72 [9619316.001]
  • [Cites] Am J Obstet Gynecol. 2001 Feb;184(3):354-5 [11228486.001]
  • [Cites] Kidney Int Suppl. 1993 Feb;40:S75-80 [8445842.001]
  • [Cites] J Clin Gastroenterol. 1988 Dec;10(6):663-6 [3068304.001]
  • [Cites] J R Soc Med. 1987 Apr;80(4):252-3 [3585894.001]
  • [Cites] Am J Obstet Gynecol. 1970 Jun 15;107(4):538-45 [4316407.001]
  • [Cites] Br J Anaesth. 2001 Sep;87(3):507-9 [11517142.001]
  • [Cites] Masui. 1997 Mar;46(3):413-5 [9095620.001]
  • (PMID = 20498801.001).
  • [ISSN] 2005-7563
  • [Journal-full-title] Korean journal of anesthesiology
  • [ISO-abbreviation] Korean J Anesthesiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2872861
  • [Keywords] NOTNLM ; Hydrothorax / Hypoxia / Pseudo-Meigs' syndrome
  •  go-up   go-down


43. Taylor DD, Gercel-Taylor C: MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol; 2008 Jul;110(1):13-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer.
  • While expression patterns of a recently identified biomarker family, microRNA, appear to be characteristic of tumor type and developmental origin, microRNA profiling has been limited to tissue specimens.
  • Tumors actively release exosomes into the peripheral circulation and we now demonstrate the association of microRNAs with circulating tumor-derived exosomes.
  • METHODS: Circulating tumor exosomes were isolated using a modified MACS procedure with anti-EpCAM.
  • Initially, microRNA profiles of ovarian tumors were compared to those of tumor exosomes isolated from the same patients.
  • Levels of 8 microRNAs (miR-21, miR-141, miR-200a, miR-200c, miR-200b, miR-203, miR-205 and miR-214) previously demonstrated as diagnostic, were compared in exosomes isolated from sera specimens of women with benign disease and various stages of ovarian cancer.
  • RESULTS: MicroRNA from ovarian tumor cells and exosomes from the same patients were positive for 218 of 467 mature microRNAs analyzed.
  • While EpCAM-positive exosomes were detectable in both patients with benign ovarian disease and ovarian cancer, exosomal microRNA from ovarian cancer patients exhibited similar profiles, which were significantly distinct from profiles observed in benign disease.
  • CONCLUSIONS: These results suggest that microRNA profiling of circulating tumor exosomes could potentially be used as surrogate diagnostic markers for biopsy profiling, extending its utility to screening asymptomatic populations.
  • [MeSH-major] Biomarkers, Tumor / blood. MicroRNAs / genetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Endocytosis. Female. Gene Expression Profiling. Humans. Lipid Bilayers. Neoplasm Staging. RNA, Neoplasm / blood. RNA, Neoplasm / genetics

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2008 Jul;110(1):1-2 [18589207.001]
  • [ErratumIn] Gynecol Oncol. 2010 Jan;116(1):153
  • (PMID = 18589210.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA98166
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Lipid Bilayers; 0 / MicroRNAs; 0 / RNA, Neoplasm
  •  go-up   go-down


44. Freedman RS, Wang E, Voiculescu S, Patenia R, Bassett RL Jr, Deavers M, Marincola FM, Yang P, Newman RA: Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res; 2007 Oct 1;13(19):5736-44
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer.
  • EXPERIMENTAL DESIGN: We first employed electrospray tandem mass spectrometry to determine tissue-specific concentrations of the eicosanoids prostaglandin E2 (PGE2), the hydroxyeicosatetraenoic acids (12-HETE and 5-HETE), and leukotriene (LTB4), selected for tumor growth potential, and two other bioactive lipids (15-HETE and 13-HODE) with tumor cell proliferation interference potential.
  • Tissues used included EOC tumor, tumor-free malignant peritoneum (MP), and benign peritoneum (BP) from patients with benign pelvic disease.
  • RESULTS: (a) Eicosanoid products were detected in tumor, MP, and BP specimens.
  • Neither 15-HETE nor 13-HODE showed a significant opposite trend toward levels found in BP. (b) Tissue specimens representing common EOC histotypes showed strong coexpressions of cyclooxygenases (COX-1) and prostaglandin E synthases (PGES-1) on tumor cells, whereas intratumoral or peritumoral MO/MA coexpressed COX-1 and COX-2 and PGES-1 and PGES-2, respectively. (c) cDNA microarray analysis of MP, BP, and tumor showed that a number of eicosanoid and arachidonic acid pathway genes were differentially expressed in MP and BP compared with tumor, except for CYP2J2, which was increased in tumors.
  • CONCLUSIONS: Elevated levels of eicosanoid metabolites in tumors and differential expression of eicosanoid and arachidonic acid pathway genes in the peritoneum support the involvement of bioactive lipids in the inflammatory tumor environment of EOC.
  • [MeSH-minor] Antigens, CD / biosynthesis. Antigens, Differentiation, Myelomonocytic / biosynthesis. Arachidonic Acid / chemistry. Dinoprostone / metabolism. Female. Gene Expression Profiling. Humans. Inflammation. Lipids / chemistry. Microscopy, Confocal. Models, Biological. Receptors, Cell Surface / biosynthesis. Spectrometry, Mass, Electrospray Ionization

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17908963.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD163 antigen; 0 / Eicosanoids; 0 / Lipids; 0 / Receptors, Cell Surface; 27YG812J1I / Arachidonic Acid; K7Q1JQR04M / Dinoprostone
  •  go-up   go-down


45. de León DC, Pérez-Montiel D, Bandera A, Villegas C, Gonzalez-Conde E, Vilchis JC: Perivascular epithelioid cell tumor of abdominal origin. Ann Diagn Pathol; 2010 Jun;14(3):173-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perivascular epithelioid cell tumor of abdominal origin.
  • Perivascular epithelioid tumor is not a common disease; therefore, large series are not available in the literature, and most are case reports.
  • All these neoplasms have the characteristic perivascular epithelioid cell or "PEC," but the term myomelanocyte tumor has been proposed because of the immunohistochemistry expression.
  • We report 3 cases of abdominal PEComa, 1 of them with benign clinical outcome and 2 with an aggressive behavior.
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Fatal Outcome. Female. Humans. Immunohistochemistry. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20471562.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


46. Guo H, Keefe KA, Kohler MF, Chan JK: Juvenile granulosa cell tumor of the ovary associated with tuberous sclerosis. Gynecol Oncol; 2006 Jul;102(1):118-20
MedlinePlus Health Information. consumer health - Tuberous Sclerosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Juvenile granulosa cell tumor of the ovary associated with tuberous sclerosis.
  • BACKGROUND: Tuberous sclerosis is a neurocutaneous syndrome characterized by benign tumors that can affect many organs.
  • CASE REPORT: We report the first case of an 8-year-old white female with tuberous sclerosis and juvenile granulosa cell tumor of the ovary.
  • [MeSH-major] Granulosa Cell Tumor / complications. Ovarian Neoplasms / complications. Tuberous Sclerosis / complications
  • [MeSH-minor] Child. Female. Humans

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16516278.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Anderson NS, Turner L, Livingston S, Chen R, Nicosia SV, Kruk PA: Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation. J Ovarian Res; 2009;2:16
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bcl-2 expression is altered with ovarian tumor progression: an immunohistochemical evaluation.
  • BACKGROUND: Ovarian cancer is the most lethal gynecologic malignancy.
  • The ovarian tumor microenvironment is comprised of tumor cells, surrounding stroma, and circulating lymphocytes, an important component of the immune response, in tumors.
  • Therefore, we sought to examine Bcl-2 expression in normal, benign, and cancerous ovarian tissues to determine the potential relationship between epithelial and stromal Bcl-2 expression in conjunction with the presence of lymphocytes for epithelial ovarian tumor progression.
  • METHODS: Ovarian tissue sections were classified as normal (n = 2), benign (n = 17) or cancerous (n = 28) and immunohistochemically stained for Bcl-2.
  • RESULTS: While Bcl-2 staining remained cytoplasmic, both percent and intensity of epithelial and stromal Bcl-2 staining decreased with tumor progression.
  • Further, the number of lymphocyte nests dramatically increased with tumor progression.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]
  • [Cites] Mol Cell Endocrinol. 2001 Apr 25;175(1-2):29-39 [11325514.001]
  • [Cites] Int J Oncol. 2001 May;18(5):965-72 [11295042.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2061 [10561259.001]
  • [Cites] Endocr Relat Cancer. 1999 Mar;6(1):93-107 [10732792.001]
  • [Cites] Cancer Res. 2000 Mar 1;60(5):1254-60 [10728684.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):409-17 [10666369.001]
  • [Cites] Cancer. 2009 Jul 1;115(13):2891-902 [19472394.001]
  • [Cites] Int J Gynecol Cancer. 2009 Jan;19(1):58-64 [19258943.001]
  • [Cites] Mod Pathol. 2009 Mar;22(3):393-402 [19060844.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):60-7 [19007973.001]
  • [Cites] Breast. 2008 Dec;17(6):604-10 [18656354.001]
  • [Cites] Adv Exp Med Biol. 2008;622:79-87 [18546620.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] J Cell Physiol. 2007 Dec;213(3):581-8 [17708542.001]
  • [Cites] J Proteome Res. 2007 Aug;6(8):2936-62 [17583933.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):316-24 [16505286.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] J Surg Oncol. 2005 Dec 15;92(4):337-43 [16299808.001]
  • [Cites] Am J Pathol. 2005 Sep;167(3):797-812 [16127158.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):97-101 [15661539.001]
  • [Cites] Breast Cancer Res. 2005;7(1):33-6 [15642180.001]
  • [Cites] Mol Biol Cell. 1999 Apr;10(4):1221-34 [10198068.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):517-24 [9516944.001]
  • [Cites] Cancer Res. 1996 May 1;56(9):2178-84 [8616869.001]
  • [Cites] J Cell Physiol. 1997 Nov;173(2):261-5 [9365533.001]
  • [Cites] Br J Urol. 1997 Apr;79 Suppl 2:18-26 [9126066.001]
  • [Cites] Am J Clin Pathol. 1996 Mar;105(3):341-9 [8602616.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1324-9 [7577491.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):67-74 [7557618.001]
  • [Cites] Obstet Gynecol. 1993 Aug;82(2):181-6 [8336861.001]
  • [Cites] Int J Dev Biol. 1993 Mar;37(1):203-11 [8507562.001]
  • [Cites] Biol Reprod. 1991 Apr;44(4):717-24 [1710511.001]
  • [Cites] Int J Cell Cloning. 1991 Sep;9(5):438-50 [1955735.001]
  • [Cites] Int J Cancer. 1991 Apr 1;47(6):843-6 [2010226.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jun;83(12):4167-71 [2424019.001]
  • [Cites] Adv Cancer Res. 1988;50:159-96 [3287842.001]
  • [Cites] Cancer Res. 1989 May 15;49(10):2750-4 [2713858.001]
  • [Cites] Clin Cancer Res. 2004 Jul 1;10(13):4450-6 [15240536.001]
  • [Cites] Int J Gynecol Cancer. 2002 May-Jun;12(3):265-76 [12060448.001]
  • (PMID = 19852858.001).
  • [ISSN] 1757-2215
  • [Journal-full-title] Journal of ovarian research
  • [ISO-abbreviation] J Ovarian Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2774291
  •  go-up   go-down


48. Chang W, Oiseth SJ, Orentlicher R, Agarwal G, Yahr LJ, Cayten CG: Bilateral sclerosing stromal tumor of the ovaries in a premenarchal girl. Gynecol Oncol; 2006 May;101(2):342-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sclerosing stromal tumor of the ovaries in a premenarchal girl.
  • BACKGROUND: Sclerosing stromal tumor of the ovary is a rare benign neoplasm that is usually unilateral in menstruating women with a mean age of 27.
  • CASE: An 11-year-old girl presented with asymptomatic bilateral sclerosing stromal tumor of the ovaries prior to menarche.
  • CONCLUSION: We herein report a unique case of bilateral sclerosing stromal tumor of the ovaries arising in a premenarchal girl.
  • [MeSH-minor] Child. Female. Humans. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16403568.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Piura B, Rabinovich A, Sinelnikov I, Delgado B: Tailgut cyst initially misdiagnosed as ovarian tumor. Arch Gynecol Obstet; 2005 Oct;272(4):301-3
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tailgut cyst initially misdiagnosed as ovarian tumor.
  • It is usually benign and located in the retrorectal/presacral space.
  • The initial diagnosis was neoplasm of the right ovary.
  • [MeSH-minor] Diagnosis, Differential. Female. Histocytochemistry. Humans. Hysterectomy. Middle Aged. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16041543.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


50. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr: The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol; 2008 Feb;108(2):402-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
  • OBJECTIVES: The CA125 tumor marker is used to help predict the presence of ovarian cancer in patients with an adnexal mass.
  • Because elevated CA125 levels occur in many benign gynecologic conditions, we set out to identify other novel biomarkers that would increase the sensitivity and specificity of CA125.
  • Of these, 233 patients were eligible for analysis with 67 invasive epithelial ovarian cancers and 166 benign ovarian neoplasms.
  • Mean values for all marker levels except Her2 differed significantly between patients with benign masses and cancer.
  • CONCLUSIONS: As a single tumor marker, HE4 had the highest sensitivity for detecting ovarian cancer, especially Stage I disease.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / urine. Ovarian Neoplasms / blood. Ovarian Neoplasms / urine. Pelvic Neoplasms / blood. Pelvic Neoplasms / urine
  • [MeSH-minor] Adnexa Uteri / pathology. Aged. CA-125 Antigen / blood. CA-125 Antigen / urine. Epididymal Secretory Proteins / metabolism. Female. Humans. Middle Aged. Prospective Studies. Sensitivity and Specificity. beta-Defensins


51. Capo-chichi CD, Yeasky TM, Heiber JF, Wang Y, Barber GN, Xu XX: Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models. Gynecol Oncol; 2010 Feb;116(2):269-75
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Explicit targeting of transformed cells by VSV in ovarian epithelial tumor-bearing Wv mouse models.
  • Specifically, we examined the toxicity to hosts and specificity of targeting ovarian tumors using a Wv ovarian tumor model.
  • Then, we tested VSV oncolytic therapy using the immune competent Wv mice that develop tubular adenomas, benign tumor lesions derived from ovarian surface epithelial cells.
  • The epithelial tumor lesions were greatly reduced in VSV-targeted ovarian tumors in the Wv mice.
  • The results demonstrated the explicit targeting of ovarian epithelial tumors by VSV in immune competent, ovarian tumor-bearing mouse models, and further support the utility of VSV as an effective and safe anti-cancer agent.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Elsevier Inc. All rights reserved.
  • [Cites] Nat Med. 2000 Jul;6(7):821-5 [10888934.001]
  • [Cites] J Virol. 2000 Oct;74(20):9580-5 [11000229.001]
  • [Cites] J Virol. 2001 Apr;75(7):3474-9 [11238874.001]
  • [Cites] J Virol. 2002 Jan;76(2):895-904 [11752178.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3605-11 [12839948.001]
  • [Cites] J Virol. 2003 Aug;77(16):8843-56 [12885903.001]
  • [Cites] Cancer Res. 2003 Aug 15;63(16):4967-77 [12941822.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):19-24 [14749123.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):51-65 [14749126.001]
  • [Cites] Trends Mol Med. 2004 May;10(5):210-6 [15121047.001]
  • [Cites] Hum Gene Ther. 2004 Sep;15(9):821-31 [15353037.001]
  • [Cites] J Natl Cancer Inst. 1972 May;48(5):1283-95 [4337905.001]
  • [Cites] J Cell Physiol. 1988 Mar;134(3):347-56 [2450877.001]
  • [Cites] Genes Dev. 1990 Mar;4(3):390-400 [1692559.001]
  • [Cites] EMBO J. 1990 Jun;9(6):1805-13 [1693331.001]
  • [Cites] Lab Invest. 1990 Jul;63(1):132-6 [2374399.001]
  • [Cites] J Virol. 2004 Dec;78(23):12747-61 [15542627.001]
  • [Cites] Viral Immunol. 2004;17(4):516-27 [15671748.001]
  • [Cites] Hepatology. 2005 Jan;41(1):196-203 [15619242.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12(4):350-8 [15565179.001]
  • [Cites] Mol Ther. 2007 Apr;15(4):651-9 [17299401.001]
  • [Cites] Am J Pathol. 2007 Apr;170(4):1325-36 [17392171.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1291-5 [18316546.001]
  • [Cites] J Mol Med (Berl). 2008 Apr;86(4):363-77 [18214411.001]
  • [Cites] Cancer Res. 2008 Jun 15;68(12):4506-10 [18559493.001]
  • [Cites] Semin Oncol. 2009 Apr;36(2):112-25 [19332246.001]
  • [Cites] Annu Rev Pathol. 2009;4:287-313 [18842102.001]
  • [Cites] Nat Rev Cancer. 2009 Jun;9(6):415-28 [19461667.001]
  • [Cites] Mol Cell Biol. 2009 Sep;29(17):4766-77 [19581290.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7710-9 [16299531.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):965-76 [16294217.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):349-58 [16186807.001]
  • [Cites] Curr Opin Mol Ther. 2006 Aug;8(4):322-30 [16955695.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1546-57 [17077357.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2840-8 [17363607.001]
  • (PMID = 19932656.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083638-100010; United States / NCI NIH HHS / CA / R01 CA079716-11; United States / NCI NIH HHS / CA / CA095924-06; United States / NCI NIH HHS / CA / R01 CA099471-05; United States / NCI NIH HHS / CA / R01 CA095924-05; United States / NCI NIH HHS / CA / R01 CA79716; United States / NCI NIH HHS / CA / R01 CA099471; United States / NCI NIH HHS / CA / R01 CA75389; United States / NCI NIH HHS / CA / R01 CA079716; United States / NIAID NIH HHS / AI / R01 AI071193-01A2; United States / NIAID NIH HHS / AI / R01 AI071193; United States / NCI NIH HHS / CA / CA095924-05; United States / NCI NIH HHS / CA / CA083638-100010; United States / NCI NIH HHS / CA / CA128115-01A2; United States / NCI NIH HHS / CA / R01 CA095924-06; United States / NCI NIH HHS / CA / P01 CA128115-01A2; United States / NCI NIH HHS / CA / CA079716-11; United States / NIAID NIH HHS / AI / AI071193-01A2; United States / NCI NIH HHS / CA / P01 CA128115; United States / NCI NIH HHS / CA / P50 CA083638; United States / NIAID NIH HHS / AI / R01 AI079336; United States / NCI NIH HHS / CA / R01 CA095924; United States / NCI NIH HHS / CA / CA099471-05
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS161338; NLM/ PMC2813895
  •  go-up   go-down


52. Yamaguchi K, Kaku T, Enjoji M, Kato M, Anai M, Kawakita M, Hamasaki N, Tanaka M: [Urine diacetylspermine as a novel tumor marker]. Rinsho Byori; 2005 Feb;53(2):130-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Urine diacetylspermine as a novel tumor marker].
  • A urine tumor marker, diacetylspermine, was examined in patients with recurrent pancreato-biliary carcinoma, liver tumor, lung carcinoma and gynecologic malignancies.
  • Concerning uterine cervical tumor, the value of the urine marker increased with the grade of dysplasia.
  • The sensitivity for ovarian carcinoma was 100%, while that for benign ovarian tumor was 0%.
  • These findings suggest that urine diacetylspermine is a useful tumor marker in hepatocellular carcinoma, lung cancer and gynecologic malignancy as well as pancreatobiliary carcinoma.
  • [MeSH-major] Biliary Tract Neoplasms / diagnosis. Biomarkers, Tumor / urine. Genital Neoplasms, Female / diagnosis. Liver Neoplasms / diagnosis. Lung Neoplasms / diagnosis. Neoplasm Recurrence, Local / diagnosis. Pancreatic Neoplasms / diagnosis. Spermine / analogs & derivatives. Spermine / urine
  • [MeSH-minor] Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796046.001).
  • [ISSN] 0047-1860
  • [Journal-full-title] Rinsho byori. The Japanese journal of clinical pathology
  • [ISO-abbreviation] Rinsho Byori
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 2FZ7Y3VOQX / Spermine; 77928-71-3 / N',N''-diacetylspermine
  • [Number-of-references] 6
  •  go-up   go-down


53. Coosemans A, Moerman P, Verbist G, Maes W, Neven P, Vergote I, Van Gool SW, Amant F: Wilms' tumor gene 1 (WT1) in endometrial carcinoma. Gynecol Oncol; 2008 Dec;111(3):502-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Wilms' tumor gene 1 (WT1) in endometrial carcinoma.
  • OBJECTIVE: Wilms' tumor gene (WT1), located on chromosome 11, encodes a transcription factor that contributes to the carcinogenesis of uterine sarcomas.
  • Three slides from different sites of the tumor were analysed.
  • To compare, WT1 expression was also evaluated by IHC in benign endometrium (12) and benign endometrial polyps (5).
  • RESULTS: WT1 positivity was noticed in tumor cells and endothelial cells, lining the intratumoral blood vessels.
  • Comparing the staining patterns of the 3 different bioptic sites, tumor heterogeneity was demonstrated in the majority (72%) of samples.
  • [MeSH-major] Endometrial Neoplasms / genetics. Genes, Wilms Tumor
  • [MeSH-minor] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / metabolism. Adenocarcinoma, Clear Cell / pathology. Aged. Biopsy. Carcinoma, Endometrioid / genetics. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / genetics. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Female. Humans. Immunohistochemistry. Neoplasm Staging. Reverse Transcriptase Polymerase Chain Reaction. WT1 Proteins / biosynthesis. WT1 Proteins / genetics

  • Genetic Alliance. consumer health - Wilms' tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18929401.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / WT1 Proteins
  •  go-up   go-down


54. Piura B: Placental site trophoblastic tumor--a challenging rare entity. Eur J Gynaecol Oncol; 2006;27(6):545-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Placental site trophoblastic tumor--a challenging rare entity.
  • Placental site trophoblastic tumor (PSTT) is a challenging rare variant of gestational trophoblastic disease (GTD) with variable characteristics.
  • Historically, it was first described in 1895 and was considered a benign lesion until Scully and Young recognized its malignant potential in 1981.
  • [MeSH-major] Chorionic Gonadotropin, beta Subunit, Human / blood. Trophoblastic Tumor, Placental Site / surgery. Uterine Neoplasms / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers. Female. Humans. Pregnancy. Prognosis

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17290581.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Chorionic Gonadotropin, beta Subunit, Human
  • [Number-of-references] 23
  •  go-up   go-down


55. Amoura Z, Duhaut P, Huong DL, Wechsler B, Costedoat-Chalumeau N, Francès C, Cacoub P, Papo T, Cormont S, Touitou Y, Grenier P, Valeyre D, Piette JC: Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Cancer Epidemiol Biomarkers Prev; 2005 May;14(5):1279-82
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor antigen markers for the detection of solid cancers in inflammatory myopathies.
  • We have assessed the diagnostic values of serum tumor markers for the detection of solid cancer in dermatomyositis/polymyositis patients.
  • All the patients had complete physical examination, chest X-ray, echocardiogram, gastrointestinal tract endoscopic explorations, thoracoabdomino-pelvic computed tomography scan, and all women had gynecologic examination and mammogram.
  • Exclusion criteria for study were childhood dermatomyositis, inclusion body myositis, myositis associated with a connective tissue disease, prior history of cancer, and the presence of benign conditions known to elevate serum tumor markers.
  • [MeSH-major] Antigens, Tumor-Associated, Carbohydrate / blood. Carcinoembryonic Antigen / blood. Dermatomyositis / diagnosis. Neoplasms, Unknown Primary / diagnosis. Polymyositis / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / blood. Cohort Studies. Female. France / epidemiology. Humans. Immunoradiometric Assay. Male. Middle Aged. Paraneoplastic Syndromes / diagnosis. Paraneoplastic Syndromes / epidemiology. Risk Factors

  • Genetic Alliance. consumer health - Myositis, inclusion body.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15894686.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


56. Taylor DD, Gercel-Taylor C, Parker LP: Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer. Gynecol Oncol; 2009 Oct;115(1):112-20
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patient-derived tumor-reactive antibodies as diagnostic markers for ovarian cancer.
  • Our objective was to validate our array assay for the identification of ovarian cancer based on quantitation of tumor-reactive IgG.
  • Specific protein targets were isolated by immunoaffinity from exosomes derived from ovarian tumor cell lines.
  • Sera were obtained from age-matched female volunteers, women with benign ovarian disease and with ovarian cancer.
  • RESULTS: Sera from ovarian cancer patients exhibited significantly greater immunoreactivities than either normal controls or women with benign disease (both considered negative to all antigens tested).
  • Reactivities with nucleophosmin, cathepsin D, p53, and SSX common antigen for patients with all stages of ovarian cancer were significantly higher than for controls and women with benign ovarian disease.
  • CONCLUSIONS: The quantitation of circulating tumor-reactive IgG can be used to identify the presence of ovarian cancer.
  • The analyses of IgG recognition of specific exosomal antigens allows for the differentiation of women with benign ovarian masses from ovarian cancer, as well as distinguishing early and late stage ovarian cancers.
  • Thus, the quantitative assessment of IgG reactive with specific tumor-derived exosomal proteins can be used as diagnostic markers for ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 1993 Oct 21;55(4):678-84 [8406999.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):26-35 [8380118.001]
  • [Cites] J Cell Biochem Suppl. 1995;23:189-99 [8747396.001]
  • [Cites] J Soc Gynecol Investig. 1996 Jul-Aug;3(4):216-22 [8796833.001]
  • [Cites] Gynecol Oncol. 1997 Apr;65(1):13-22 [9103385.001]
  • [Cites] Cancer Lett. 1997 Jun 3;116(1):93-101 [9177463.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] Oncol Rep. 1998 Nov-Dec;5(6):1519-24 [9769398.001]
  • [Cites] J Proteome Res. 2005 Jul-Aug;4(4):1123-33 [16083262.001]
  • [Cites] Expert Rev Mol Diagn. 2005 Sep;5(5):735-43 [16149876.001]
  • [Cites] N Engl J Med. 2005 Sep 22;353(12):1288-90 [16177255.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1181-90 [16424057.001]
  • [Cites] Biochim Biophys Acta. 2006 Apr;1762(4):398-403 [16483750.001]
  • [Cites] PLoS One. 2007;2(12):e1281 [18060075.001]
  • [Cites] Clin Cancer Res. 2008 Feb 1;14(3):764-71 [18245537.001]
  • [Cites] Adv Exp Med Biol. 2008;622:15-21 [18546615.001]
  • [Cites] PLoS Med. 2008 Aug 19;5(8):e170 [18715113.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2009 Feb;142(2):99-105 [18995946.001]
  • [Cites] Methods Mol Biol. 2009;520:21-38 [19381945.001]
  • [Cites] Clin Biochem. 2000 Feb;33(1):53-62 [10693987.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;46 Suppl:S3-7 [10950139.001]
  • [Cites] Br J Cancer. 2000 Nov;83(10):1338-43 [11044359.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4060-5 [11274429.001]
  • [Cites] Gynecol Oncol. 2001 Apr;81(1):71-6 [11277653.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):138-43 [11330940.001]
  • [Cites] Cancer Detect Prev. 2001;25(2):117-22 [11341346.001]
  • [Cites] Int J Oncol. 2001 Aug;19(2):387-94 [11445857.001]
  • [Cites] J Reprod Med. 2001 Jul;46(7):621-9; discussion 629-30 [11499181.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14571-6 [11724951.001]
  • [Cites] Int J Cancer. 2001 Dec 15;94(6):859-63 [11745489.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):168s-174s [12743131.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):720-6 [15252841.001]
  • [Cites] Nature. 1970 Aug 15;227(5259):680-5 [5432063.001]
  • [Cites] Anal Biochem. 1979 Sep 15;98(1):53-9 [396817.001]
  • [Cites] Am J Reprod Immunol. 1984 Dec;6(4):179-84 [6528883.001]
  • [Cites] Cancer Res. 1989 Mar 15;49(6):1361-5 [2924293.001]
  • [Cites] Am J Pathol. 1992 Apr;140(4):859-70 [1314027.001]
  • [Cites] Lancet. 1995 Jan 14;345(8942):126 [7815863.001]
  • (PMID = 19647308.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA098166-02; United States / NCI NIH HHS / CA / R21 CA098166-02
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Biomarkers, Tumor; 0 / Epitopes; 0 / Immunoglobulin G
  • [Other-IDs] NLM/ NIHMS129188; NLM/ PMC2760307
  •  go-up   go-down


57. Suh-Burgmann E: Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study. Gynecol Oncol; 2006 Dec;103(3):841-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcomes following conservative surgery for borderline tumor of the ovary: a large population-based study.
  • OBJECTIVES: To examine outcomes in women treated with conservative surgery for borderline ovarian tumor in a large population-based cohort with long-term follow-up.
  • METHODS: Women treated by conservative surgery for borderline tumor of the ovary from 1982-2004 within a large HMO setting were identified using electronic and tumor registry data.
  • The indications for and outcomes from any subsequent gynecologic surgery and the risk of recurrent ovarian borderline and malignant tumor were determined.
  • There were 21 recurrences with borderline tumor (11%) with a median time to first recurrence of 4.7 years; women treated by cystectomy recurred three times more often compared to women treated by oophorectomy (23% versus 7%).
  • During long-term follow-up, 19% of patients eventually underwent complete removal of ovarian tissue: in 8%, the surgery was prophylactic, in 5%, surgery was done for benign pathology, and in 6% for recurrent disease.
  • CONCLUSIONS: In this population-based HMO setting, 11% of women treated with conservative surgery for borderline tumor recurred; however, half of these recurrences were successfully managed by repeat conservative surgery, with only 6% of women overall needing eventual complete removal of ovaries for recurrent disease.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Ovarian Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. California / epidemiology. Child. Cohort Studies. Disease-Free Survival. Female. Fertility. Gynecologic Surgical Procedures / methods. Gynecologic Surgical Procedures / utilization. Health Maintenance Organizations. Humans. Medical Records. Middle Aged. Neoplasm Staging. Postoperative Complications. Registries. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793124.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


58. He Y, Yang KX, Yang F, Wu XL: Primary solitary fibrous tumor of the vulva: a case report. J Reprod Med; 2010 Sep-Oct;55(9-10):452-6
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary solitary fibrous tumor of the vulva: a case report.
  • BACKGROUND: Solitary fibrous tumor (SFT) of the female genital tract is an extremely rare neoplasm of mesenchymal origin.
  • The tumor presented as a 10-cm, well-circumscribed lump and was composed of bland-looking cells admixed with thin and thick collagen fibers with the appearance of hemangiopericytoma.
  • Microscopic evaluation and immunohistochemistry supported the diagnosis of a primary benign vulvar SFT.
  • The outcome of this tumor is based mostly on complete surgical resection.
  • [MeSH-minor] Adult. Female. Gynecologic Surgical Procedures. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21043376.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Gungor T, Altinkaya SO, Akbay S, Bilge U, Mollamahmutoglu L: Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review. Arch Gynecol Obstet; 2010 Mar;281(3):485-90
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malign mural nodules associated with serous ovarian tumor of borderline malignancy: a case report and literature review.
  • BACKGROUND: Cystic tumors of ovary, whether benign, borderline, or malignant may be associated with mural nodule of various types, including sarcomas, sarcoma-like mural nodules (SLMN), and foci of anaplastic carcinoma.
  • Cases of serous borderline ovarian tumor with mural nodules of mixed type are very rare.
  • Left ureter was found to be dilated because of the infiltration of distal part by the tumor, so distal ureteral resection and neoureterocystostomy were performed.
  • Final pathology revealed borderline serous ovarian tumor with mural nodules which were consisted of SLMNs, multiple and sharply demarcated from the adjacent tumor, and sarcomatous nodules showing infiltrative appearance in metastatic regions.
  • [MeSH-minor] Anaplasia / pathology. Female. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19597831.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 39
  •  go-up   go-down


60. Kabaca C, Karateke A, Gurbuz A, Cesur S: Androgenic adult granulosa cell tumor in a teenager: a case report and review of the literature. Int J Gynecol Cancer; 2006 Jan-Feb;16 Suppl 1:368-74
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgenic adult granulosa cell tumor in a teenager: a case report and review of the literature.
  • The clinicopathologic findings of the third case of androgenic adult granulosa cell tumor in patients younger than 15 years was presented and discussed in the light of the literature.
  • Inhibin A could be a tumor marker of utmost importance particularly in patients with androgenic or hyperestrogenic symptoms, especially in cases where benign criteria are abundant such as young age, nonincreased levels of classic tumor markers, and ultrasonographic appearance without any suspicion of malignancy.
  • [MeSH-major] Biomarkers, Tumor / blood. Granulosa Cell Tumor / diagnosis. Inhibins / blood. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Amenorrhea / etiology. Androgens / blood. Androstenols / blood. Female. Gynecologic Surgical Procedures. Hirsutism / etiology. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16515626.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Androstenols; 0 / Biomarkers, Tumor; 0 / inhibin A; 57285-09-3 / Inhibins
  • [Number-of-references] 29
  •  go-up   go-down


61. Sieunarine K, Cowie AS, Bartlett JD, Lindsay I, Smith JR: A novel approach in the management of a recurrent adenomatoid tumor of the uterus utilizing a Strassman technique. Int J Gynecol Cancer; 2005 Jul-Aug;15(4):671-5
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel approach in the management of a recurrent adenomatoid tumor of the uterus utilizing a Strassman technique.
  • Adenomatoid tumors of the uterus are uncommon benign lesions derived from mesothelium, with a prevalence of 1.2% in one study of 1 000 unselected hysterectomy specimens.
  • This transpired to be an adenomatoid tumor, and she underwent three transcervical resections of the tumor (TCRT) over a period of 12 months for tumor recurrence and failure of symptom resolution.
  • A specialist opinion on the suitability of vascular embolization of the tumor judged that it would be ineffective for this lesion.
  • She then underwent a Strassman procedure and removal of the adenomatoid tumor.
  • This involved dissection of ureters and pelvic vasculature, selective temporary ligation of uterine arteries, hemisection of the uterus, and excision of the tumor with frozen sections to ensure clear tumor margins and resuturing of the uterine halves.
  • Temporary vascular occlusion of the uterine arteries and ovarian vessels allowed a Strassman procedure, which resulted in successful resection of a recurrent giant adenomatoid tumor of the uterus, with fertility preservation in a young nulliparous woman.
  • Two and a half years on there is no evidence of tumor recurrence.
  • [MeSH-major] Adenomatoid Tumor / surgery. Gynecologic Surgical Procedures / methods. Neoplasm Recurrence, Local / surgery. Uterine Neoplasms / surgery. Uterus / blood supply
  • [MeSH-minor] Adult. Female. Humans. Ligation. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16014122.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


62. Berveiller P, Mir O, Menu Y, Jamali M, Carbonne B: Fertility-sparing approach in a teenager with uterine tumor diagnosed as a sarcoma on imaging. Gynecol Obstet Invest; 2010;69(3):157-9
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fertility-sparing approach in a teenager with uterine tumor diagnosed as a sarcoma on imaging.
  • CASE REPORT: An 18-year-old female patient presented with marked anemia, and a rapidly growing uterine tumor that strongly suggested uterine sarcoma on MRI.
  • In order to avoid dispensable radical surgery, explorative laparotomy with tumor biopsy was performed after balancing risk/benefit ratio.
  • Extemporaneous pathologic examination revealed a benign leiomyoma, and the patient subsequently underwent complete conservative myomectomy.
  • CONCLUSION: Preserving fertility is an important issue in young patients with uterine tumors, and tumor biopsy may overcome MRI false positive results, as illustrated in this case.
  • [MeSH-major] Infertility, Female / prevention & control. Leiomyoma / pathology. Leiomyoma / surgery. Sarcoma / pathology. Uterine Neoplasms / pathology. Uterine Neoplasms / surgery
  • [MeSH-minor] Adolescent. Biopsy. Diagnosis, Differential. False Positive Reactions. Female. Fertility. Humans. Magnetic Resonance Imaging. Uterus / pathology. Uterus / surgery


63. Salamon C, Tornos C, Chi DS: Borderline endometrioid tumor arising in a paratubal cyst: a case report. Gynecol Oncol; 2005 Apr;97(1):263-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline endometrioid tumor arising in a paratubal cyst: a case report.
  • The following represents the first reported case of an endometrioid tumor of low malignant potential arising in a paratubal cyst.
  • CASE REPORT: A 45-year-old nulliparous female was referred with a complex right adnexal mass on pelvic sonogram.
  • All frozen-section diagnoses were benign; however, final pathology revealed a borderline tumor of low malignant potential of endometrioid type in the right paratubal cyst.
  • Final pathologic analysis revealed no evidence of persistent borderline tumor.
  • Laparoscopic surgery is an option in the management of adnexal masses; however, rupture or puncture of masses should be avoided when possible to prevent potential tumor dissemination in the event of a malignancy.
  • [MeSH-minor] Broad Ligament / pathology. Female. Humans. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15790473.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Gagnon A, Kim JH, Schorge JO, Ye B, Liu B, Hasselblatt K, Welch WR, Bandera CA, Mok SC: Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res; 2008 Feb 1;14(3):764-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients.
  • Therefore, the possibility of using autoantibodies directed against tumor-associated antigens as putative cancer markers is being more examined.
  • To do so, we developed an innovative technique called two-dimensional differential gel electrophoresis analysis of immunoprecipitated tumor antigens.
  • Further real-time reverse transcription-PCR and immunohistochemical studies confirmed that the S100A7 mRNA and protein were highly expressed in ovarian tumors but absent in normal and benign tissues.
  • Moreover, a preliminary study involving 138 patients confirmed that the plasma levels of anti-S100A7 antibodies are significantly elevated in early- and late-stage ovarian cancer patients compared with healthy controls and with patients with benign gynecologic diseases.
  • CONCLUSIONS: This shows that our approach is a valuable tool to successfully identify autoantibodies and tumor-associated antigens in cancer patients and that future research assessing their putative clinical usefulness would be worthwhile.
  • [MeSH-major] Antigens, Neoplasm / blood. Autoantibodies / blood. Ovarian Neoplasms / immunology
  • [MeSH-minor] Cell Line, Tumor. Electrophoresis, Gel, Two-Dimensional. Female. Humans. Immunoglobulin G / blood. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18245537.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA105009; United States / NCI NIH HHS / CA / R33CA103595; United States / NCI NIH HHS / CA / UO1CA86381
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies; 0 / Immunoglobulin G; 0 / RNA, Messenger; 0 / RNA, Neoplasm
  •  go-up   go-down


65. Sakurai H, Suzuki Y, Nonaka T, Ishikawa H, Shioya M, Kiyohara H, Katoh H, Nakayama Y, Hasegawa M, Nakano T: FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value. Gynecol Oncol; 2006 Mar;100(3):601-7
International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in the detection of recurrence of uterine cervical carcinoma following radiation therapy--tumor volume and FDG uptake value.
  • Rationale for FDG-PET was the presence of symptoms in 6 patients, abnormal serum tumor marker values in 13, abnormal lesions on other diagnostic imaging modalities in 19, and patient request in 2.
  • Maximum tumor diameter and tumor volume in the corresponding disease were estimated by computed tomography (CT) or magnetic resonance imaging (MRI).
  • Three false-positive cases were a localized pneumonitis, a benign pubic bone fracture, and a fibrosis after interstitial brachytherapy.
  • Regarding tumor volume measurement, good correlation between maxSUV on FDG-PET and tumor volume was obtained (lung metastases, P = 0.03; extrapelvic nodes, P < 0.0001).
  • This study suggests that FDG uptake is associated with tumor volume, and FDG-PET has limitations in the detection of lesions less than 1 cm3 or microscopic disease.
  • Careful diagnostic agreement between PET and CT/MRI for positive but benign lesions, such as inflammation and bone fracture, remains important.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Uterine Cervical Neoplasms / radionuclide imaging
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Positron-Emission Tomography

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16257440.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


66. Koensgen D, Mustea A, Klaman I, Sun P, Zafrakas M, Lichtenegger W, Denkert C, Dahl E, Sehouli J: Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression. Gynecol Oncol; 2007 Nov;107(2):266-73
SciCrunch. HGNC: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
  • OBJECTIVE: The plasminogen activator system (PA) plays an important role in invasion and metastasis of solid tumors.
  • A thorough expression analysis of PAI-RBP1 and PAI-1 was performed in normal ovary (n=4), benign (n=6) and malignant (n=42) ovarian lesions using non-radioactive RNA in situ hybridization and immunohistochemistry, respectively.
  • RESULTS: PAI-RBP1 mRNA and PAI-1 were significantly overexpressed in tumor epithelial cells as compared to benign and normal ovarian tissue.
  • CONCLUSION: In ovarian cancer, PAI-RBP1 is significantly overexpressed in tumor epithelial cells, suggesting a biological role in tumor invasion and metastasis.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma / chemistry. Carcinoma / pathology. Ovarian Neoplasms / chemistry. Ovarian Neoplasms / pathology. Plasminogen Activator Inhibitor 1 / analysis. Retinol-Binding Proteins, Cellular / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Disease Progression. Female. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. In Situ Hybridization. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Neoplasm, Residual. Predictive Value of Tests. Prognosis. RNA, Messenger / analysis. RNA, Neoplasm / analysis. Survival Analysis. Up-Regulation


67. Davidson B, Elstrand MB, McMaster MT, Berner A, Kurman RJ, Risberg B, Trope CG, Shih IeM: HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol Oncol; 2005 Jan;96(1):42-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
  • OBJECTIVE: We recently showed that the levels of secreted human leukocyte antigen-G (HLA-G), a nonclassical MHC class I antigen, are significantly elevated in malignant effusions in ovarian carcinoma compared to benign ones.
  • HLA-G expression in tumor cells was significantly lower in effusions obtained during or following chemotherapy (P = 0.038).
  • The presence of HLA-G-positive tumor cells in effusions obtained prior to the institution of chemotherapy correlated with better overall survival (P = 0.042).
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. HLA Antigens / biosynthesis. Histocompatibility Antigens Class I / biosynthesis. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antibodies, Monoclonal / chemistry. Ascitic Fluid / immunology. Female. HLA-G Antigens. Humans. Immunohistochemistry. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Pleural Effusion / immunology. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15589578.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / HLA Antigens; 0 / HLA-G Antigens; 0 / Histocompatibility Antigens Class I
  •  go-up   go-down


68. Fan T, Zhao Q, Chen JJ, Chen WT, Pearl ML: Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol Oncol; 2009 Jan;112(1):185-91
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer.
  • OBJECTIVES: The invasive growth of circulating tumor cells (CTCs) propagates cancer metastasis.
  • METHODS: Peripheral blood samples from 71 patients undergoing evaluation for ovarian malignancy were assessed for the presence of invasive CTCs using a cell invasion assay that enriches and identifies tumor cells with a cell adhesion matrix (CAM).
  • RESULTS: 43 (60.6%) patients had detectable CTCs: 0/5 benign patients, 1/10 (10%) early stage, 39/52 (73.1%) late stage and 3/4 (75%) unstaged patients (p-value <0.001).
  • CTC counts ranged from 0-149 CTCs/ml with stage III/IV patients exhibiting significantly higher mean counts (41.3 CTCs/ml) than stage I/II patients (6.0 CTCs/ml) and benign patients (0 CTCs/ml, p-value=0.001).
  • Tumor grade and tumor histology did not influence CTC detection.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2002 Feb 1;94(3):707-12 [11857303.001]
  • [Cites] Gynecol Oncol. 2003 Nov;91(2):389-94 [14599871.001]
  • [Cites] Curr Opin Cell Biol. 2003 Dec;15(6):740-6 [14644200.001]
  • [Cites] Cancer Res. 1984 Aug;44(8):3584-92 [6744281.001]
  • [Cites] Gynecol Oncol. 1990 Sep;38(3):442-5 [2227559.001]
  • [Cites] N Engl J Med. 2004 Dec 9;351(24):2519-29 [15590954.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4652-61 [16651416.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):942-7 [16889820.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S161-92 [17161157.001]
  • [Cites] Pathology. 2007 Jun;39(3):305-18 [17558857.001]
  • [Cites] Cancer Lett. 2007 Aug 18;253(2):180-204 [17314005.001]
  • [Cites] Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1047-55 [17433065.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Clin Exp Metastasis. 2008;25(2):171-81 [18058027.001]
  • [Cites] Nat Med. 2000 Jan;6(1):100-2 [10613833.001]
  • [Cites] Mol Diagn. 2000 Mar;5(1):33-8 [10837087.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):785-92 [10997804.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):368-75 [11208828.001]
  • (PMID = 18954898.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA103467-01; United States / NIBIB NIH HHS / EB / EB002065-21; United States / NCI NIH HHS / CA / CA108247-02; United States / NCI NIH HHS / CA / R42 CA108247-04; United States / NIBIB NIH HHS / EB / R01 EB002065-21; United States / NCRR NIH HHS / RR / RR010710-070061; United States / NCI NIH HHS / CA / CA108247-03; United States / NCI NIH HHS / CA / R42 CA108247-03; United States / NCI NIH HHS / CA / R42 CA108247-01; United States / NCI NIH HHS / CA / R41 CA103467-01; United States / NCI NIH HHS / CA / CA108247-04; United States / NCI NIH HHS / CA / CA039077-23; United States / NCI NIH HHS / CA / R42 CA108247-02; United States / NCI NIH HHS / CA / R01 CA039077-23; United States / NCI NIH HHS / CA / CA108247-01; United States / NCRR NIH HHS / RR / M01 RR010710-070061
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  • [Other-IDs] NLM/ NIHMS69436; NLM/ PMC2606929
  •  go-up   go-down


69. Zhang Z, Yu Y, Xu F, Berchuck A, van Haaften-Day C, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Skates S, Chan DW, Bast RC Jr: Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer. Gynecol Oncol; 2007 Dec;107(3):526-31
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combining multiple serum tumor markers improves detection of stage I epithelial ovarian cancer.
  • OBJECTIVE: Currently available tumor markers for ovarian cancer are still inadequate in both sensitivity and specificity to be used for population-based screening.
  • The four tumor marker values were then used as inputs to an ANN derived using a training set from 100 apparently healthy women, 45 women with benign conditions arising from the ovary and 55 invasive epithelial ovarian cancer patients (including 27 stage I/II cases).
  • A separate validation set from 27 apparently healthy women, 56 women with benign conditions and 35 women with various types of malignant pelvic masses was used to monitor the ANN's performance during training.
  • An independent test data set from 98 apparently healthy women and 52 early stage epithelial ovarian cancer patients (38 stage I and 4 stage II invasive cases and 10 stage I borderline ovarian tumor cases) was used to evaluate the ANN.
  • CONCLUSIONS: The combined use of multiple tumor markers through an ANN improves the overall accuracy to discern healthy women from patients with early stage ovarian cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 1999 Apr;73(1):56-61 [10094881.001]
  • [Cites] Lancet. 1997 Aug 16;350(9076):469-72 [9274582.001]
  • [Cites] Int J Biol Markers. 1998 Oct-Dec;13(4):216-20 [10228904.001]
  • [Cites] Gynecol Oncol. 2000 Jun;77(3):350-6 [10831341.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):582-8 [10931457.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2837-44 [11753957.001]
  • [Cites] Cancer Treat Res. 2002;107:61-97 [11775462.001]
  • [Cites] Int J Cancer. 2002 Apr 10;98(5):737-40 [11920644.001]
  • [Cites] Ann N Y Acad Sci. 2002 Jun;963:204-12 [12095945.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Gynecol Oncol. 1985 Sep;22(1):115-20 [2410329.001]
  • [Cites] Obstet Gynecol. 1986 Mar;67(3):414-6 [2418395.001]
  • [Cites] Gynecol Oncol. 1988 May;30(1):7-14 [2452773.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] Am J Obstet Gynecol. 1991 Nov;165(5 Pt 1):1356-62 [1957862.001]
  • [Cites] BMJ. 1993 Apr 17;306(6884):1025-9 [8490496.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Gynecol Oncol. 1995 Oct;59(1):111-6 [7557595.001]
  • [Cites] Lancet. 1996 Jan 6;347(8993):12-5 [8531540.001]
  • [Cites] Cancer. 1995 Nov 15;76(10 Suppl):2004-10 [8634992.001]
  • [Cites] BMJ. 1996 Nov 30;313(7069):1355-8 [8956699.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • (PMID = 17920110.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / 1P50 CA83639; United States / NCI NIH HHS / CA / CA083639-07; United States / NCI NIH HHS / CA / U24 CA115102; United States / NCI NIH HHS / CA / CA115102-03; United States / NCI NIH HHS / CA / P50 CA083639-07; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / U24 CA115102-03; United States / NCI NIH HHS / CA / CA080459-01; United States / NCI NIH HHS / CA / R43 CA080459-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / CA-125 Antigen; 0 / CA-72-4 antigen; 0 / Mucin-1; 81627-83-0 / Macrophage Colony-Stimulating Factor
  • [Other-IDs] NLM/ NIHMS35835; NLM/ PMC2171045
  •  go-up   go-down


70. Youm HS, Cha DS, Han KH, Park EY, Hyon NN, Chong Y: A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman. J Gynecol Oncol; 2008 Dec;19(4):270-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of huge sclerosing stromal tumor of the ovary weighing 10 kg in a 71-year-old postmenopausal woman.
  • Sclerosing stromal tumor (SST) is a rare benign neoplasm of ovarian stromal origin and predominantly affects young women in the second and third decades.
  • This tumor characteristically differentiates itself histologically and clinically from both thecomas and fibromas.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 2003 Oct;443(4):549-60 [12910419.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):318-9 [11330969.001]
  • [Cites] Obstet Gynecol. 1975 Jun;45(6):675-9 [1143729.001]
  • [Cites] Adv Anat Pathol. 2007 Sep;14(5):305-19 [17717430.001]
  • [Cites] AJR Am J Roentgenol. 2005 Jul;185(1):207-15 [15972425.001]
  • [Cites] Ultrasound Obstet Gynecol. 2003 Nov;22(5):531-4 [14618669.001]
  • [Cites] Gynecol Oncol. 1976 Sep;4(3):335-9 [964703.001]
  • [Cites] Cancer. 1973 Mar;31(3):664-70 [4348335.001]
  • [Cites] Clin Radiol. 2000 Dec;55(12):899-911 [11124069.001]
  • [Cites] Int J Gynaecol Obstet. 2003 Dec;83(3):319-21 [14643050.001]
  • [Cites] Histopathology. 1979 Sep;3(5):367-76 [488921.001]
  • (PMID = 19471655.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676485
  • [Keywords] NOTNLM ; Ovary / Sclerosing stromal tumor
  •  go-up   go-down


71. Liao SY, Rodgers WH, Kauderer J, Bonfiglio TA, Walker JL, Darcy KM, Carter R, Hatae M, Levine L, Spirtos NM, Stanbridge EJ: Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States. Int J Cancer; 2009 Nov 15;125(10):2434-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Carbonic anhydrase IX and human papillomavirus as diagnostic biomarkers of cervical dysplasia/neoplasia in women with a cytologic diagnosis of atypical glandular cells: a Gynecologic Oncology Group study in United States.
  • In the cervix, carbonic anhydrase IX (CA-IX) is expressed in cervical neoplasia, but rarely in the benign cervix.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • COS Scholar Universe. author profiles.
  • International Agency for Research on Cancer - Screening Group. diagnostics - A practical manual on visual screening for cervical neoplasia .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 1999 Jul;30(7):816-25 [10414501.001]
  • [Cites] Am J Obstet Gynecol. 1998 Aug;179(2):382-90 [9731842.001]
  • [Cites] Diagn Cytopathol. 2006 Mar;34(3):235-9 [16470857.001]
  • [Cites] Am J Obstet Gynecol. 2005 Aug;193(2):559-65; discussion 565-7 [16098895.001]
  • [Cites] Vaccine. 2008 Aug 19;26 Suppl 10:K1-16 [18847553.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1007-13 [16803477.001]
  • [Cites] J Clin Microbiol. 2006 Nov;44(11):3915-7 [16971652.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer. 2000 Mar 1;88(5):1108-21 [10699902.001]
  • [Cites] Gynecol Oncol. 2000 Aug;78(2):97-105 [10926787.001]
  • [Cites] Am J Pathol. 2000 Oct;157(4):1055-62 [11021808.001]
  • [Cites] Am J Pathol. 2001 Mar;158(3):905-19 [11238039.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3660-8 [11504747.001]
  • [Cites] Cancer Res. 2001 Sep 1;61(17):6394-9 [11522632.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):222-7 [11668502.001]
  • [Cites] Am J Clin Pathol. 2002 Jan;117(1):96-102 [11789738.001]
  • [Cites] Cancer. 2002 Feb 25;96(1):1-4 [11836696.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]
  • [Cites] Diagn Cytopathol. 2003 Nov;29(5):271-9 [14595795.001]
  • [Cites] Am J Clin Pathol. 2004 Jan;121(1):87-92 [14750245.001]
  • [Cites] Gynecol Oncol. 1989 Oct;35(1):1-7 [2792895.001]
  • [Cites] Acta Cytol. 1993 Mar-Apr;37(2):115-24 [8465628.001]
  • [Cites] Int J Cancer. 1993 May 8;54(2):268-74 [8486430.001]
  • [Cites] Am J Pathol. 1994 Sep;145(3):598-609 [8080042.001]
  • [Cites] Oncogene. 1994 Oct;9(10):2877-88 [8084592.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1996 Jul;5(7):549-57 [8827360.001]
  • [Cites] Gynecol Oncol. 1996 Oct;63(1):14-8 [8898161.001]
  • [Cites] Cancer Res. 1997 Jul 15;57(14):2827-31 [9230182.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1248-54 [18483347.001]
  • (PMID = 19670419.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA037517-25; United States / NCI NIH HHS / CA / CA027469-29; United States / NCI NIH HHS / CA / CA 11479; United States / NCI NIH HHS / CA / CA 27469; United States / NCI NIH HHS / CA / U10 CA027469; United States / NCI NIH HHS / CA / U10 CA037517; None / None / / U10 CA037517-25; United States / NCI NIH HHS / CA / CA 37517; United States / NCI NIH HHS / CA / U10 CA027469-29
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Viral; EC 4.2.1.1 / CA9 protein, human; EC 4.2.1.1 / Carbonic Anhydrases
  • [Other-IDs] NLM/ NIHMS137629; NLM/ PMC2779726
  •  go-up   go-down


72. Barra Ade A, Gobbi H, de L Rezende CA, Gouvêa AP, de Lucena CE, Reis JH, Costa e Silva SZ: A comparision of aspiration cytology and core needle biopsy according to tumor size of suspicious breast lesions. Diagn Cytopathol; 2008 Jan;36(1):26-31
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparision of aspiration cytology and core needle biopsy according to tumor size of suspicious breast lesions.
  • The purpose of the study was to compare the accuracy of FNAC, CNB, and combined biopsy according to tumor size of suspicious breast lesions.
  • The lesions were divided in four groups according to the tumor size in the histopathology report: lesions smaller than 1 cm, between 1 and 2 cm, between 2 and 5 cm, and lesions greater than 5 cm.
  • The final surgical histopatology results identified 222 (84%) malignant cases and benign lesions summed 42 (16%).
  • [MeSH-minor] Breast / pathology. Female. Humans. Predictive Value of Tests. Sensitivity and Specificity. Ultrasonography, Mammary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18064684.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Bese T, Barbaros M, Baykara E, Guralp O, Cengiz S, Demirkiran F, Sanioglu C, Arvas M: Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer. J Gynecol Oncol; 2010 Dec 30;21(4):248-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of total plasma lysophosphatidic acid and serum CA-125 as a tumor marker in the diagnosis and follow-up of patients with epithelial ovarian cancer.
  • OBJECTIVE: To evaluate the role of lysophosphatidic acid (LPA) as a tumor marker in diagnosis and follow-up of patients with epithelial ovarian cancer.
  • METHODS: Eighty-seven epithelial ovarian cancer patients, 74 benign ovarian tumor patients, and 50 healthy women were enrolled in the study.
  • RESULTS: Preoperative total plasma LPA and serum CA-125 levels were significantly higher in patients with epithelial ovarian cancer compared to patients with benign ovarian tumors and healthy women.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1999 Oct 15;59(20):5370-5 [10537322.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Clin Cancer Res. 1999 Dec;5(12):4308-18 [10632375.001]
  • [Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]
  • [Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]
  • [Cites] J Biol Chem. 2002 Dec 13;277(50):48737-44 [12354767.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2234-42 [15781636.001]
  • [Cites] Cancer Res. 2006 Mar 15;66(6):3006-14 [16540649.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]
  • [Cites] Eur J Gynaecol Oncol. 2007;28(5):394-9 [17966220.001]
  • [Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]
  • [Cites] Eur J Gynaecol Oncol. 2008;29(5):511-4 [19051824.001]
  • [Cites] Clin Cancer Res. 1995 Oct;1(10):1223-32 [9815916.001]
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):326-30 [10684705.001]
  • [Cites] Ann N Y Acad Sci. 2000 Apr;905:188-208 [10818454.001]
  • [Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]
  • [Cites] J Clin Invest. 1981 Nov;68(5):1331-7 [7028788.001]
  • [Cites] Biochem J. 1995 Aug 1;309 ( Pt 3):933-40 [7639713.001]
  • [Cites] Biochem J. 1993 May 1;291 ( Pt 3):677-80 [8489494.001]
  • [Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]
  • [Cites] JAMA. 1998 Aug 26;280(8):719-23 [9728644.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):444-50 [11104617.001]
  • [Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]
  • [Cites] J Natl Cancer Inst. 2001 May 16;93(10):762-8 [11353786.001]
  • [Cites] Eur J Gynaecol Oncol. 2001;22(5):372-6 [11766744.001]
  • [Cites] JAMA. 2002 Jun 19;287(23):3081-2 [12069669.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]
  • [Cites] J Lipid Res. 2003 Oct;44(10):1963-75 [12837850.001]
  • [Cites] Biochem Pharmacol. 1963 Apr;12:415-20 [13997687.001]
  • [Cites] J Biol Chem. 2004 Mar 5;279(10):9653-61 [14670967.001]
  • [Cites] J Clin Invest. 1990 Sep;86(3):851-5 [2394835.001]
  • [Cites] Obstet Gynecol. 1987 Feb;69(2):223-7 [2433652.001]
  • [Cites] Cancer Res. 1988 Mar 1;48(5):1066-71 [3422589.001]
  • [Cites] Br J Obstet Gynaecol. 1987 Mar;94(3):196-201 [3471273.001]
  • [Cites] Am J Obstet Gynecol. 1984 Jul 1;149(5):553-9 [6204531.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]
  • (PMID = 21278887.001).
  • [ISSN] 2005-0399
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC3026304
  • [Keywords] NOTNLM ; CA-125 / Chemotherapy / Epithelial ovarian cancer / Follow-up / Lysophosphatidic acid / Tumor marker
  •  go-up   go-down


74. Schlott T, Eiffert H, Bohne W, Landgrebe J, Brunner E, Spielbauer B, Knight B: Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue. Gynecol Oncol; 2005 Sep;98(3):409-19
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue.
  • OBJECTIVES: The obligate intracellular bacterium Chlamydia trachomatis is frequently found in association with benign proliferative, pre-neoplastic and malignant changes in cervical epithelium.
  • The cultures showed a 2-fold decrease in the expression of the gene coding for the tumor suppressor caveolin-1, and increased expression of the oncogene C-myc, a promoter of cervical carcinogenesis.
  • [MeSH-major] Caveolins / genetics. Cell Transformation, Neoplastic / genetics. Cervix Uteri / microbiology. Chlamydia trachomatis / physiology. Genes, Tumor Suppressor / physiology. Genes, myc / genetics. Uterine Cervical Neoplasms / genetics. Uterine Cervical Neoplasms / microbiology
  • [MeSH-minor] Caveolin 1. Chlamydia Infections / complications. Chlamydia Infections / genetics. Chlamydia Infections / microbiology. Female. Fibroblasts / cytology. Fibroblasts / drug effects. Fibroblasts / microbiology. Humans. Interferon-gamma / pharmacology. Oligonucleotide Array Sequence Analysis. Proto-Oncogene Proteins c-myc / biosynthesis. Proto-Oncogene Proteins c-myc / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation


75. Papantoniou V, Koutsikos J, Sotiropoulou M, Feida E, Tsiouris S: Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography. Gynecol Oncol; 2005 Jun;97(3):964-9
Hazardous Substances Data Bank. TECHNETIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent bilateral mammary fibromatosis (desmoid tumor) imaged with technetium-99m pentavalent dimercaptosuccinic acid [99mTc-(V)DMSA] scintimammography.
  • BACKGROUND: Breast fibromatosis is a rare, benign, recurring, locally destructive entity.
  • [MeSH-major] Breast Neoplasms / radionuclide imaging. Fibromatosis, Aggressive / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Radiopharmaceuticals. Technetium. Technetium Tc 99m Dimercaptosuccinic Acid
  • [MeSH-minor] Adult. Female. Humans. Mammography / methods

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • Genetic Alliance. consumer health - Fibromatosis.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15896828.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 494JNQ8L28 / Technetium Tc 99m Dimercaptosuccinic Acid; 7440-26-8 / Technetium
  •  go-up   go-down


76. Loffroy R, Nezzal N, Mejean N, Sagot P, Krausé D: Lipoleiomyoma of the uterus: imaging features. Gynecol Obstet Invest; 2008;66(2):73-5
MedlinePlus Health Information. consumer health - Uterine Fibroids.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lipoleiomyoma is an extremely rare, benign, uterine tumor that requires no treatment when asymptomatic.
  • On T(2)-weighted MR images, fat content within the tumor was confirmed because of evident chemical shift artifact.To our knowledge, the findings provided by these three modalities used in combination have not been reported previously in the gynecologic literature.
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Female. Histocytochemistry. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 S. Karger AG, Basel.
  • (PMID = 18431071.001).
  • [ISSN] 1423-002X
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


77. Canis M, Jardon K, Niro J, Rabischong B, Bourdel N, Botchorishvili R, Pouly JL, Mage G: [Endoscopic management of gynecological malignancies: an update. 2007]. Bull Acad Natl Med; 2007 Oct;191(7):1357-65; discussion 1365-6
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All the different surgical procedures used to treat gynecologic cancers have already been performed with the endoscopic approach.
  • Animal studies suggest that the risk of tumor dissemination in the non traumatized peritoneum may be higher after pneumoperitoneum than after laparotomy, and they also show the importance of the surgeon's experience and technique.
  • By controlling these parameters we may, in future, be able to create a peritoneal environment suitable for oncologic indications and thereby prevent or minimize the risk of peritoneal dissemination and postoperative tumor growth.
  • In contrast, restaging of early ovarian cancer initially managed as a benign mass is a good indication for the laparoscopic approach.
  • Training in endoscopic oncological techniques will be a major challenge in the field of gynecologic surgery in coming years.
  • [MeSH-major] Endoscopy / methods. Genital Neoplasms, Female / surgery. Gynecologic Surgical Procedures / methods
  • [MeSH-minor] Animals. Carcinoma / secondary. Carcinoma / surgery. Endometrial Neoplasms / surgery. Female. Humans. Neoplasm Seeding. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritoneal Neoplasms / secondary. Pneumoperitoneum, Artificial / adverse effects. Pneumoperitoneum, Artificial / methods. Swine. Uterine Cervical Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18447057.001).
  • [ISSN] 0001-4079
  • [Journal-full-title] Bulletin de l'Académie nationale de médecine
  • [ISO-abbreviation] Bull. Acad. Natl. Med.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 30
  •  go-up   go-down


78. Anderson NS, Bermudez Y, Badgwell D, Chen R, Nicosia SV, Bast RC Jr, Kruk PA: Urinary levels of Bcl-2 are elevated in ovarian cancer patients. Gynecol Oncol; 2009 Jan;112(1):60-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Bcl-2 was assayed by ELISA in urine samples from two cohorts consisting of a total of 77 healthy women, 161 women with benign gynecologic disease and 150 women with ovarian cancer, 13 with early and 137 with late stage disease, respectively.
  • RESULTS: Urinary levels of Bcl-2 from healthy individuals or women with benign disease averaged 0.59 ng/ml+/-0.61 and 1.12 ng/ml+/-0.79, respectively.
  • Further, urinary levels of Bcl-2 were elevated in ovarian cancer patients regardless of tumor grade, stage, size, histologic subtype, creatinine levels or patient age, but appeared to complement CA125 measurements.
  • [MeSH-major] Biomarkers, Tumor / urine. Ovarian Neoplasms / urine. Proto-Oncogene Proteins c-bcl-2 / urine
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CA-125 Antigen / blood. Cohort Studies. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Neoplasm Staging. Risk Factors

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Detect Prev. 2002;26(2):149-57 [12102150.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1453-5 [12205045.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):720-7 [12445249.001]
  • [Cites] J Cell Sci. 2003 Nov 15;116(Pt 22):4493-9 [14576343.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2074-80 [12931228.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):162-9 [15084845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1185-91 [15247129.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Carcinogenesis. 2000 Mar;21(3):485-95 [10688869.001]
  • [Cites] Int J Mol Med. 2000 May;5(5):547-51 [10762660.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):12-8 [10739646.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):19-26 [10739647.001]
  • [Cites] Exp Cell Res. 2000 Apr 10;256(1):58-66 [10739652.001]
  • [Cites] JAMA. 2001 Jan 17;285(3):324-8 [11176843.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2183-8 [11280784.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Genet Dev. 1996 Feb;6(1):45-9 [8791486.001]
  • [Cites] J Biol Chem. 1999 Apr 16;274(16):11245-52 [10196212.001]
  • [Cites] Clin Cancer Res. 1999 Apr;5(4):823-9 [10213218.001]
  • [Cites] Clin Cancer Res. 2004 Nov 15;10(22):7457-65 [15569975.001]
  • [Cites] Cancer Detect Prev. 2005;29(3):256-9 [15899555.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):490-7 [17532030.001]
  • [Cites] Clin Cancer Res. 2007 Dec 15;13(24):7296-304 [18094410.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • (PMID = 19007973.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / P50 CA083639
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2
  • [Other-IDs] NLM/ NIHMS232262; NLM/ PMC3729448
  •  go-up   go-down


79. Jazaeri AA, Ferriss JS, Bryant JL, Dalton MS, Dutta A: Evaluation of EVI1 and EVI1s (Delta324) as potential therapeutic targets in ovarian cancer. Gynecol Oncol; 2010 Aug 1;118(2):189-95
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Expression of EVI1 mRNA and protein isoforms was evaluated in ovarian cancers, normal ovaries, benign ovarian neoplasms, and fallopian tube fimbria.
  • RESULTS: EVI1 and EVI1s mRNAs were ubiquitously expressed in ovarian cancers and benign gynecologic tissues examined, with highest expression of both isoforms noted in the cancer samples.
  • EVI1 protein expression patterns were similar between serous ovarian cancer samples, fallopian tube fimbria, and benign neoplasms.
  • [MeSH-minor] Apoptosis / drug effects. Apoptosis / genetics. Cell Growth Processes / drug effects. Cell Growth Processes / genetics. Cell Line, Tumor. Cisplatin / pharmacology. DNA Damage. Drug Delivery Systems. Female. Gene Knockdown Techniques. Humans. Middle Aged. Protein Isoforms. Proto-Oncogenes / genetics. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20462630.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / MECOM protein, human; 0 / Protein Isoforms; 0 / RNA, Messenger; 0 / Transcription Factors; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


80. De Sousa Damião R, Fujiyama Oshima CT, Stávale JN, Gonçalves WJ: Analysis of the expression of estrogen receptor, progesterone receptor and chicken ovalbumin upstream promoter-transcription factor I in ovarian epithelial cancers and normal ovaries. Oncol Rep; 2007 Jul;18(1):25-32
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sex hormones are involved in the carcinogenesis of some gynecologic cancers, and the status of their receptors represents an indicator of prognosis and of the therapeutic response in breast and endometrial cancers.
  • To investigate the role of these receptors in ovarian carcinogenesis and their implications for cancer prognosis, we evaluated the immunohistochemical expression of ER, progesterone receptor (PR) and COUP-TFI in benign and malignant ovarian epithelial neoplasms and in normal ovaries.
  • A total of 113 ovarian specimens, including 40 diagnosed as malignant epithelial neoplasms (group A), 45 as benign epithelial tumors (group B), and 28 from normal ovaries (group C) were analyzed.
  • Multivariate analysis revealed a residual tumor <1 cm as the most significant clinical prognostic factor in group A (p=0.010, OR=4.14).
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Gene Expression Regulation. Humans. Middle Aged. Prospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549341.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / COUP Transcription Factor I; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


81. Tsukishiro S, Suzumori N, Nishikawa H, Arakawa A, Suzumori K: Elevated serum RANTES levels in patients with ovarian cancer correlate with the extent of the disorder. Gynecol Oncol; 2006 Sep;102(3):542-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the clinical relevance of serum regulated upon activation, normal T-cell expressed and secreted (RANTES) levels in distinguishing patients with ovarian cancers from those with benign ovarian cysts, we measured its concentration with reference to the disease stage, pathological grading, histological subtype, and the residual tumor mass.
  • METHODS: Preoperative serum RANTES levels were measured in women with invasive epithelial ovarian cancer (n = 52), borderline ovarian tumor (n = 6), benign ovarian cysts (n = 28), or normal controls (n = 12) using an enzyme-linked immunosorbent assay.
  • RESULTS: The serum RANTES concentration was significantly elevated in the ovarian cancer patients (median 53 ng/ml, interquartile range 23-104 ng/ml) compared to the benign ovarian cyst patients as controls (38 ng/ml, 5-72 ng/ml) values correlating with the stage of disease and the extent of residual tumor mass.
  • CONCLUSION: Our study suggest that preoperative serum RANTES levels may be useful in differentiating benign ovarian tumors from malignancy correlating with the extent of the disorder.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Diagnosis, Differential. Female. Humans. Middle Aged. Ovarian Cysts / diagnosis. Statistics as Topic

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16510173.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Chemokine CCL5
  •  go-up   go-down


82. Lee CH, Turbin DA, Sung YC, Espinosa I, Montgomery K, van de Rijn M, Gilks CB: A panel of antibodies to determine site of origin and malignancy in smooth muscle tumors. Mod Pathol; 2009 Dec;22(12):1519-31
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Leiomyosarcomas are malignant smooth muscle tumors that occur most commonly in the gynecologic tract and soft tissue.
  • There are different diagnostic criteria of malignancy for smooth muscle tumors arising at gynecologic and soft tissue sites and they may be managed differently but determining the primary site of a smooth muscle tumor can be difficult in some cases.
  • In addition, the distinction between malignant and benign gynecologic tract smooth muscle tumors on morphologic grounds can be challenging.
  • Using a series of tissue microarrays that contain 245 cases of leiomyosarcomas (102 gynecologic) with survival data, and 49 cases of uterine leiomyoma, we examined the ability of selected immune-markers (estrogen receptor (ER) and WT1) to distinguish between leiomyosarcomas of gynecologic and nongynecologic origin.
  • In addition, we examined whether immunostains for p16, p53 and Ki-67 could distinguish between malignant and benign gynecologic smooth muscle tumors.
  • ER nuclear positivity was observed in 3 and 50% of the nongynecologic and gynecologic leiomyosarcomas, respectively (P<0.001).
  • Nuclear WT1 positivity was seen in 0 and 8% of the nongynecologic and gynecologic leiomyosarcomas, respectively (P<0.001).
  • 87% of primary gynecologic leiomyosarcomas and 2% of uterine leiomyomas showed diffuse (>or=50% of cells) p16 staining (P<0.001).
  • 23% of gynecologic leiomyosarcomas showed p53 immunopositivity (>or=50% of cells) whereas none of the leiomyomas were positive for p53 (P<0.001).
  • 65% of the gynecologic leiomyosarcomas and 0% of the leiomyomas exhibited >10% Ki-67 proliferation index (P<0.001).
  • Diffuse p16 and p53 immunopositivity and high Ki-67 proliferation index, singly or in combination, yielded an overall sensitivity of 92% and specificity of 98% for distinguishing between gynecologic leiomyosarcomas and leiomyomas and can be used as indicators of malignancy for gynecologic smooth muscle tumors.
  • Although ER positivity can be used to support the gynecologic origin of a leiomyosarcomas, nuclear WT1 immunostaining is of little use.
  • [MeSH-minor] Adult. Antibodies. Biomarkers, Tumor / analysis. Canada. Cell Nucleus / chemistry. Cyclin-Dependent Kinase Inhibitor p16 / analysis. Diagnosis, Differential. Europe. Female. Humans. Kaplan-Meier Estimate. Ki-67 Antigen / analysis. Male. Middle Aged. Predictive Value of Tests. Receptors, Estrogen / analysis. Sensitivity and Specificity. Tissue Array Analysis. Tumor Suppressor Protein p53 / analysis. United States

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Fibroids.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19734847.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA112270
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Biomarkers, Tumor; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53; 0 / WT1 Proteins
  •  go-up   go-down


83. McBroom JW, Acs G, Rose GS, Krivak TC, Mohyeldin A, Verma A: Erythropoietin receptor function and expression in epithelial ovarian carcinoma. Gynecol Oncol; 2005 Dec;99(3):571-7
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, immunohistochemical (IHC) staining for EpoR in tissue specimens of normal, low malignant potential tumor, and epithelial ovarian carcinoma was performed.
  • IHC staining revealed limited EpoR expression in benign ovarian tissue and increased levels in ovarian low malignant potential (LMP) tumor and carcinoma.
  • This difference between benign ovarian tissue and carcinoma was found to be statistically significant using a quantitative scoring system.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cisplatin / pharmacology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / metabolism. Cystadenoma, Serous / pathology. Drug Screening Assays, Antitumor. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16051335.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Erythropoietin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


84. Manoharan M, Azmi MA, Soosay G, Mould T, Weekes AR: Mullerian adenosarcoma of uterine cervix: report of three cases and review of literature. Gynecol Oncol; 2007 Apr;105(1):256-60
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Mullerian adenosarcoma of the uterine cervix is a rare tumor seen in young women of reproductive age group.
  • Diagnosis can be difficult since it can easily be mistaken for benign polyps, both clinically and pathologically.
  • [MeSH-major] Adenosarcoma / pathology. Mixed Tumor, Mullerian / pathology. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Adult. Female. Humans

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17292949.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


85. Rim SY, Kim SM, Choi HS: Struma ovarii showing clinical characteristics of ovarian malignancy. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1156-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Struma ovarii is a rare form of ovarian neoplasm, composed entirely or predominantly of thyroid tissue and generally a benign germ cell tumor of the ovary.
  • We experienced a rare case of a postmenopausal woman with benign struma ovarii associated with massive ascites, a complex pelvic mass.
  • No recurrence of the ascites or of the tumor has been observed during the 10-month follow-up.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Ovarian Neoplasms / pathology. Struma Ovarii / pathology. Teratoma / pathology
  • [MeSH-minor] Ascites / etiology. Female. Gynecologic Surgical Procedures. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343201.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


86. Kong F, Nicole White C, Xiao X, Feng Y, Xu C, He D, Zhang Z, Yu Y: Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecol Oncol; 2006 Feb;100(2):247-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • New biomarkers that individually or in combination improve the diagnostic performance of existing tumor markers are critically needed.
  • The first set of patients included 21 ovarian cancers, 18 benign diseases, and 20 normal patients.
  • The second set included 32 ovarian cancers, 30 benign ovarian diseases, and 30 age-matched healthy controls.
  • [MeSH-major] Biomarkers, Tumor / blood. Blood Proteins / analysis. Neoplasm Proteins / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Computational Biology. Female. Humans. Middle Aged. Neoplasm Staging. Proteomics / methods. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16229881.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Blood Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


87. Kikkawa F, Nawa A, Kajiyama H, Shibata K, Ino K, Nomura S: Clinical characteristics and prognosis of mucinous tumors of the ovary. Gynecol Oncol; 2006 Oct;103(1):171-5
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Ovarian mucinous tumors consist of benign, borderline, and carcinomatous tumor, but the clinical characteristics of these 3 types have not been investigated in detail.
  • METHODS: One hundred sixty-one patients with mucinous cystadenocarcinoma and 143 patients with mucinous borderline tumor were registered between 1986 and 2003.
  • RESULTS: Mean patient ages were 43.9, 44.7, and 49.7 years in patients with benign, borderline, carcinomatous tumor, respectively.
  • The ratio of early stage (I, II) to advanced stage (III, IV) was significantly lower in carcinoma than in borderline tumor.
  • The levels of tumor markers tended to increase with the level of malignancy.
  • In borderline tumor, 5 patients died of disease, and all of these patients had stage III disease with residual tumor after the initial surgery.
  • Patients with borderline tumor showed significantly better prognosis than those with carcinoma; however, there were no significant differences in prognosis between borderline tumor and carcinoma in patients with stage III tumor or residual tumor.
  • CONCLUSIONS: In mucinous tumors, measurement of CA72-4 is recommended to distinguish malignant from benign tumors.
  • Even in borderline tumor, patients with residual tumor showed a poorer prognosis than carcinoma, suggesting that complete resection is necessary for a good prognosis.
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / blood. Carboplatin / administration & dosage. Female. Humans. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16546243.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


88. Lee JM, Kim JW, Song JY, Lee JK, Lee NW, Kim SH, Lee KW: Adenocarcinoma arising in mature cystic teratoma: a case report. J Gynecol Oncol; 2008 Sep;19(3):199-201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign cystic teratoma is recognized as one of the most common tumors in women during the reproductive age and frequently is treated by pelviscopic operation.
  • Malignant transformation of a benign cystic teratoma is a rare event, and adenocarcinoma is extremely rare, and distinguishing this malignant change from benign disease preoperatively is nearly impossible even by the use of radiological imaging or various tumor markers.
  • We briefly reviewed literatures with regard to malignant transformation of a benign cystic teratoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Surg Pathol. 2007 Jul;15(3):318-20 [17652549.001]
  • [Cites] Pathol Res Pract. 2006;202(7):531-5 [16713128.001]
  • [Cites] Int J Gynecol Cancer. 2006 Jan-Feb;16(1):140-4 [16445624.001]
  • [Cites] Obstet Gynecol Surv. 1957 Dec;12(6):793-830 [13493921.001]
  • [Cites] Surg Endosc. 1998 Nov;12(11):1326-33 [9788856.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2249-55 [9610706.001]
  • [Cites] Obstet Gynecol Surv. 2000 Dec;55(12):738-45 [11128910.001]
  • [Cites] Gynecol Oncol. 1992 Jun;45(3):248-53 [1319383.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 1988 Dec;29(4):329-38 [3229546.001]
  • [Cites] Gynecol Oncol. 2004 Aug;94(2):597-9 [15297213.001]
  • [Cites] Pathol Int. 2004 Feb;54(2):139-43 [14720146.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):338-41 [12893196.001]
  • [Cites] Arch Gynecol Obstet. 2002 Dec;267(2):107-9 [12439559.001]
  • [Cites] Arch Pathol Lab Med. 1993 Jun;117(6):647-9 [8503739.001]
  • (PMID = 19471568.001).
  • [ISSN] 2005-0380
  • [Journal-full-title] Journal of gynecologic oncology
  • [ISO-abbreviation] J Gynecol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2676465
  • [Keywords] NOTNLM ; Adenocarcinoma / Malignant transformation / Mature cystic teratoma / Tumor marker
  •  go-up   go-down


89. Granovsky-Grisaru S, Zaidoun S, Grisaru D, Yekel Y, Prus D, Beller U, Bar-Shavit R: The pattern of Protease Activated Receptor 1 (PAR1) expression in endometrial carcinoma. Gynecol Oncol; 2006 Dec;103(3):802-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While the role of either soluble or matrix-immobilized protease in tumor invasion is well established, the part of cell surface PARs is beginning to emerge.
  • CONCLUSIONS: PAR1 over-expression is selectively confined to the highly aggressive, high-grade endometrial carcinoma and absent in tissue obtained from benign endometrium or low-grade endometrial cancer.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Endometrioid / metabolism. Endometrial Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Receptor, PAR-1 / metabolism
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Neoplasm Staging. RNA, Messenger / analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875721.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Receptor, PAR-1
  •  go-up   go-down


90. Zhang J, Ye F, Chen HZ, Ye DF, Lu WG, Xie X: [Deletion of OPCML gene and promoter methylation in ovarian epithelial carcinoma]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Apr;28(2):173-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHOD: Twenty normal ovarian tissues and 89 ovarian epithelial tumor specimens (72 malignant, 17 benign), as well as 3 ovarian carcinoma cell lines (SKOV-3, CAOV3, and 3AO), were collected for detection of OPCML gene expression by reverse transcription-polymerase chain reaction and for detection of promoter methylation by restriction enzyme cut analysis from 7.
  • RESULTS: Among ovarian epithelial carcinoma 19.4% expressed OPCML mRNA, while 85% of normal ovarian tissue and 76.5% of benign ovarian tumor.
  • The ratio of expression of OPCML mRNA in ovarian epithelial carcinoma was significantly lower than those of normal (chi2 = 30.108, P = 0.0000) and benign tumors (chi2 = 21.162, P = 0.000).
  • Methylations were detected in 44.4% of cancer cells promoter, while 0% in normal ovarian tissue and benign ovarian tumors.
  • The ratio of methylation of ovarian epithelial carcinoma was significantly higher than those of normal (chi2 = 13.630, P = 0.0000) and benign tumors (chi2 = 11.797, P = 0.000).
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. GPI-Linked Proteins. Humans. Middle Aged. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16733898.001).
  • [ISSN] 1000-503X
  • [Journal-full-title] Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
  • [ISO-abbreviation] Zhongguo Yi Xue Ke Xue Yuan Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / GPI-Linked Proteins; 0 / OPCML protein, human; 0 / RNA, Messenger
  •  go-up   go-down


91. Lutgendorf SK, Sood AK, Anderson B, McGinn S, Maiseri H, Dao M, Sorosky JI, De Geest K, Ritchie J, Lubaroff DM: Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol; 2005 Oct 1;23(28):7105-13
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the extent to which these relationships exist in immune cells in the tumor microenvironment in humans has not been explored.
  • We examined relationships among distress, social support, and natural killer (NK) cell activity in ovarian cancer patients in peripheral-blood mononuclear cells (PBMC), ascitic fluid, and tumor-infiltrating lymphocytes (TIL).
  • Samples of tumor and ascites were taken during surgery, lymphocytes were then isolated, and NK cytotoxicity and percentage were determined.
  • The final sample, which was confirmed by surgical diagnosis, included 42 patients with epithelial ovarian cancer and 23 patients with benign masses.
  • RESULTS: Peripheral NK cell activity was significantly lower among ovarian cancer patients than in patients with benign masses.
  • CONCLUSION: Psychosocial factors, such as social support and distress, are associated with changes in the cellular immune response, not only in peripheral blood, but also at the tumor level.
  • These findings support the presence of stress influences in the tumor microenvironment.
  • [MeSH-minor] Adult. Aged. Ascites. Case-Control Studies. Female. Humans. Lymphocytes, Tumor-Infiltrating. Middle Aged. Monocytes

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • MedlinePlus Health Information. consumer health - Stress.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16192594.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA1045-25; United States / NCI NIH HHS / CA / R21 CA88293
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


92. Qu D, Qu H, Fu M, Zhao X, Liu R, Sui L, Zhan Q: Increased expression of Nlp, a potential oncogene in ovarian cancer, and its implication in carcinogenesis. Gynecol Oncol; 2008 Aug;110(2):230-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Nlp expression in normal, borderline, benign and malignant epithelial ovarian tissues was examined by immunohistochemistry.
  • The correlation between Nlp expression and tumor grade, FIGO stage and histological type was also evaluated.
  • RESULTS: Nlp was positive in 1 of 10 (10%) normal ovarian tissues, 5 of 34 (14.7%) benign tumors, 9 of 26 (34.6%) borderline tumors and 73 of 131 (56.0%) ovarian tumors.
  • Nlp immunoreactivity intensity significantly correlated with tumor grade, but not with FIGO stage or histological type.
  • [MeSH-minor] Antineoplastic Agents, Phytogenic / pharmacology. Apoptosis / drug effects. Apoptosis / physiology. Cell Growth Processes / physiology. Cell Line, Tumor. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Paclitaxel / pharmacology. Survival Rate. Transfection

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18538832.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / Microtubule-Associated Proteins; 0 / NIp protein, human; 0 / Nuclear Proteins; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


93. Leiser AL, Anderson SE, Nonaka D, Chuai S, Olshen AB, Chi DS, Soslow RA: Apoptotic and cell cycle regulatory markers in uterine leiomyosarcoma. Gynecol Oncol; 2006 Apr;101(1):86-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A tissue microarray representing 36 uterine leiomyosarcomas and 19 uterine leiomyomas was created with 3 representative cores from each tumor.
  • In a multivariate analysis, tumor stage was the only independent significant prognostic factor (P = 0.002).
  • CONCLUSION: The significant differential expression of apoptotic and cell cycle regulatory proteins in uterine leiomyosarcoma as compared to benign smooth muscle tumors suggests that pathways involving these proteins may be important in the development of malignant disease and, therefore, could be potential targets for molecular therapies.
  • [MeSH-major] Apoptosis / physiology. Biomarkers, Tumor / biosynthesis. Cell Cycle / physiology. Cell Cycle Proteins / biosynthesis. Leiomyosarcoma / metabolism. Leiomyosarcoma / pathology. Uterine Neoplasms / metabolism. Uterine Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16289259.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Cycle Proteins
  •  go-up   go-down


94. Dong L, Chang XH, Ye X, Zhu LR, Zhao Y, Tian L, Cheng HY, Li XP, Zhang H, Liao QP, Fu TY, Cheng YX, Cui H: [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy]. Zhonghua Fu Chan Ke Za Zhi; 2008 Dec;43(12):931-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: HE4 and CA(125) in the serum specimens of malignant ovarian tumor group (30 cases), benign ovarian diseases (110 cases; 45 benign ovarian tumor, 57 endometriotic diseases and 8 pelvic inflammation were included) and healthy women group (137 cases) were assayed double blindly.
  • (1) The median levels of HE4 and CA(125) were significantly higher in malignant ovarian tumor group (244 pmol/L and 601 kU/L respectively) than those of the benign ovarian diseases group (32 pmol/L and 22 kU/L respectively) and healthy women group (32 pmol/L and 11 kU/L respectively) (P = 0.000 - 0.029).
  • The median levels of CA(125) were also higher in endometriotic diseases and pelvic inflammation groups (53 and 41 kU/L respectively) than those of benign ovarian tumor group and healthy women group (12 and 11 kU/L respectively; P = 0.000 - 0.031). (2) The positive rate of HE4 was lower than that of CA(125) in malignant ovarian tumor group (P = 0.036).
  • HE4 was negative in benign diseases and healthy women groups.
  • But the positive rates of CA(125) were 56.1% and 5/8 respectively in endometriotic diseases and pelvic inflammation groups and there were significant differences compared with HE4 (P = 0.000). (3) The HE4 assay had advantage over the CA(125) assay in receiver operating characteristic-area under the curve (ROC-AUC) and sensitivity with a specificity of 100% when ovarian malignancy was compared with controls having benign diseases and healthy women, benign tumor or benign diseases groups respectively.
  • The CA(125) assay had advantage over the HE4 assay in ROC-AUC and sensitivity with the same specificity when ovarian cancers were compared with controls having healthy women group. (4) Combined assay of HE4 and CA(125) was better than CA(125) alone when ovarian malignancy was compared with controls having any group. (5) Combined assay was better than HE4 alone in ROC-AUC and sensitivity with the same specificity when ovarian cancers were compared with controls having benign diseases and healthy women or healthy women groups.
  • And combined assay was lower in the ROC-AUC and the sensitivity with specificity of 100% than HE4 when ovarian cancers were compared with controls having benign tumors or benign diseases groups respectively. (6) The diagnosis efficiency of the HE4 assay at the level 86 pmol/L determined in ROC curve with controls having benign diseases and healthy women group and at the 95% reference level 50 pmol/L of healthy women or 150 pmol/L recommended by the kit respectively was compared.
  • [MeSH-major] Biomarkers, Tumor / blood. CA-125 Antigen / blood. Epididymal Secretory Proteins / analysis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Area Under Curve. Case-Control Studies. Double-Blind Method. Endometriosis / blood. Enzyme-Linked Immunosorbent Assay. Female. Humans. Middle Aged. Pelvic Neoplasms / blood. ROC Curve. Sensitivity and Specificity. Young Adult. beta-Defensins

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19134334.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / beta-Defensins
  •  go-up   go-down


95. Singhal PK, Spiegel G, Driscoll D, Odunsi K, Lele S, Rodabaugh KJ: Cyclooxygenase 2 expression in serous tumors of the ovary. Int J Gynecol Pathol; 2005 Jan;24(1):62-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study was designed to investigate the expression of cyclooxygenase (COX)-2 in ovarian serous tumors (benign, borderline tumors, and carcinomas) and primary peritoneal serous carcinomas.
  • Cases diagnosed between 1995 and 2001 were reviewed; 47 benign tumors, 6 borderline tumors, and 39 carcinomas were examined, as well as 12 normal ovaries that served as controls.
  • Normal ovarian and tubal epithelium, inclusion cysts, benign serous tumors, and borderline tumors had a uniform score 3 staining pattern.
  • Serous ovarian carcinomas had variable staining scores, tending to correlate with the level of tumor differentiation.
  • In conclusion, COX-2 expression is present in serous tumors, including benign tumors, borderline tumors, and carcinomas.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor. Case-Control Studies. Cyclooxygenase 2. Female. Humans. Immunohistochemistry. Membrane Proteins. Middle Aged. Peritoneal Neoplasms / enzymology. Peritoneal Neoplasms / pathology. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15626918.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Membrane Proteins; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human; EC 1.14.99.1 / Prostaglandin-Endoperoxide Synthases
  •  go-up   go-down


96. McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, Saunders BA, Pavlik EJ, Goodrich S, Kryscio RJ, van Nagell JR Jr: Predicting risk of malignancy in adnexal masses. Obstet Gynecol; 2010 Apr;115(4):687-94
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tumor morphology derived from ultrasonographic images, tumor size, tumor bilaterality, serum CA 125, and patient demographics were evaluated preoperatively in 395 patients undergoing surgery from 2001 to 2008.
  • Tumor morphology was classified as complex, solid, or cystic.
  • Preoperative findings were compared with tumor histologic findings at the time of surgery.
  • RESULTS: One hundred eighteen patients had ovarian cancer, 13 patients had ovarian tumors of borderline malignancy, and 264 had benign ovarian tumors.
  • [MeSH-minor] Age Factors. Biomarkers, Tumor / blood. CA-125 Antigen / blood. Female. Humans. Middle Aged. Postmenopause. Premenopause. Risk Factors. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Obstet Gynecol. 2010 Apr;115(4):680-1 [20308824.001]
  • (PMID = 20308826.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen
  •  go-up   go-down


97. Magtibay PM, Salmon Z, Keeney GL, Podratz KC: Aggressive angiomyxoma of the female pelvis and perineum: a case series. Int J Gynecol Cancer; 2006 Jan-Feb;16(1):396-401
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive angiomyxoma of the female pelvis and perineum: a case series.
  • These tumors are benign, locally infiltrative mesenchymal neoplasms with a predilection for the female pelvis and perineum and a tendency to recur.
  • Surgical excision remains the mainstay of treatment, but whether clear, tumor-free surgical margins are necessary is controversial.
  • [MeSH-major] Biomarkers, Tumor / analysis. Myxoma / pathology. Pelvic Neoplasms / pathology. Perineum / pathology
  • [MeSH-minor] Adult. Biopsy, Needle. Female. Gynecologic Surgical Procedures / methods. Humans. Immunohistochemistry. Middle Aged. Neoplasm Staging. Prognosis. Receptors, Estrogen / analysis. Receptors, Progesterone / analysis. Risk Assessment. Sampling Studies. Survival Analysis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445665.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  •  go-up   go-down


98. Goldman NA, Katz EB, Glenn AS, Weldon RH, Jones JG, Lynch U, Fezzari MJ, Runowicz CD, Goldberg GL, Charron MJ: GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod Pathol; 2006 Nov;19(11):1429-36
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The following experiments were conducted to quantify and localize the expression of GLUT1 and GLUT8 in benign endometrium and compare this expression to endometrial cancer.
  • Endometrial tissue samples were obtained from random hysterectomy specimens of patients with benign indications for surgery and endometrial cancer.
  • Endometrial samples from 65 women who had undergone hysterectomy were examined (n=38 benign, n=27 malignant).
  • GLUT8 expression was increased in all tumor subtypes compared to atrophic endometrium (P<0.001).
  • There appears to be a step-wise progression in GLUT1 and GLUT8 expression as tumor histopathology worsens.
  • GLUT1 and GLUT8 may be important markers in tumor differentiation, as well as providing energy to rapidly dividing tumor cells.
  • [MeSH-major] Adenocarcinoma / chemistry. Biomarkers, Tumor / analysis. Endometrial Neoplasms / chemistry. Endometrium / chemistry. Glucose Transport Proteins, Facilitative / analysis. Glucose Transporter Type 1 / analysis
  • [MeSH-minor] Female. Fluorescent Antibody Technique, Indirect. Humans. Up-Regulation

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16892013.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK47425; United States / NHLBI NIH HHS / HL / HL58119
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transport Proteins, Facilitative; 0 / Glucose Transporter Type 1; 0 / SLC2A1 protein, human; 0 / SLC2A8 protein, human
  •  go-up   go-down


99. Gökaslan H, Türkeri L, Kavak ZN, Eren F, Sişmanoğlu A, Ilvan S, Durmuşoğlu F: Differential diagnosis of smooth muscle tumors utilizing p53, pTEN and Ki-67 expression with estrogen and progesterone receptors. Gynecol Obstet Invest; 2005;59(1):36-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The malignant side of the spectrum was strongly stained for Ki-67 and p53 while uniformly decreasing toward the benign tumors.
  • The staining for progesterone receptor was also statistically significant, but the tumors that were considered benign, such as leiomyoma and atypical myoma, were the ones strongly stained (p = 0.005).
  • As the degree of differentiation of the tumor increased, the trend showed stronger staining for estrogen receptor.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Leiomyosarcoma / diagnosis. Smooth Muscle Tumor / diagnosis. Uterine Neoplasms / diagnosis
  • [MeSH-minor] Female. Humans. Immunohistochemistry / methods. Ki-67 Antigen / metabolism. PTEN Phosphohydrolase. Phosphoric Monoester Hydrolases / metabolism. Predictive Value of Tests. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism. Tumor Suppressor Protein p53 / metabolism. Tumor Suppressor Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel.
  • (PMID = 15377824.001).
  • [ISSN] 0378-7346
  • [Journal-full-title] Gynecologic and obstetric investigation
  • [ISO-abbreviation] Gynecol. Obstet. Invest.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Tumor Suppressor Protein p53; 0 / Tumor Suppressor Proteins; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


100. Staff AC, Bock AJ, Becker C, Kempf T, Wollert KC, Davidson B: Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol; 2010 Sep;118(3):237-43
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: GDF-15 concentration was measured by immunoradiometric assay in plasma samples from patients with invasive ovarian cancer (n=125), borderline ovarian tumor (BOT, n=43), and benign ovarian tumor (n=144), from healthy women (n=40), as well as in effusion samples (n=44) from women with advanced ovarian cancer.
  • RESULTS: Median plasma GDF-15 concentration was elevated in ovarian cancer as compared to healthy controls and women with benign ovarian tumors or BOT (p<0.001).
  • GDF-15 protein was cytoplasmatically expressed in serous tumor cells and detectable in high concentrations in effusion samples.
  • [MeSH-major] Biomarkers, Tumor / blood. Growth Differentiation Factor 15 / blood. Ovarian Neoplasms / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Immunohistochemistry. Immunoradiometric Assay. Middle Aged. Ovarian Diseases / blood. Young Adult

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20576287.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / GDF15 protein, human; 0 / Growth Differentiation Factor 15
  •  go-up   go-down






Advertisement